1
|
Jack A, Rajshekar M, Witiw CD, Curran MWT, Olson JL, Morhart MJ, Jacques L, Chan KM. Characterization of Spinal Cord Injury Patients for Arm Functional Restoration through Nerve Transfer. Can J Neurol Sci 2023:1-5. [PMID: 37545347 DOI: 10.1017/cjn.2023.255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/08/2023]
Abstract
INTRODUCTION Traumatic spinal cord injuries (tSCI) are common, often leaving patients irreparably debilitated. Therefore, novel strategies such as nerve transfers (NT) are needed for mitigating secondary SCI damage and improving function. Although different tSCI NT options exist, little is known about the epidemiological and injury-related aspects of this patient population. Here, we report such characteristics to better identify and understand the number and types of tSCI individuals who may benefit from NTs. MATERIALS AND METHODS Two peripheral nerve experts independently evaluated all adult tSCI individuals < 80 years old admitted with cervical tSCI (C1-T1) between 2005 and 2019 with documented tSCI severity using the ASIA Impairment Scale for suitability for NT (nerve donor with MRC strength ≥ 4/5 and recipient ≤ 2/5). Demographic, traumatic injury, and neurological injury variables were collected and analyzed. RESULTS A total of 709 tSCI individuals were identified with 224 (32%) who met the selection criteria for participation based on their tSCI level (C1-T1). Of these, 108 (15% of all tSCIs and 48% of all cervical tSCIs) were deemed to be appropriate NT candidates. Due to recovery, 6 NT candidates initially deem appropriate no longer qualified by their last follow-up. Conversely, 19 individuals not initially considered appropriate then become eligible by their last follow-up. CONCLUSION We found that a large proportion of individuals with cervical tSCI could potentially benefit from NTs. To our knowledge, this is the first study to detail the number of tSCI individuals that may qualify for NT from a large prospective database.
Collapse
Affiliation(s)
- Andrew Jack
- Division of Neurosurgery, Department of Surgery, University of Alberta, Edmonton, AB, Canada
| | - Mithun Rajshekar
- Division of Physical Medicine and Rehabilitation, Department of Medicine, University of Alberta, Edmonton, AB, Canada
| | - Christopher D Witiw
- Division of Neurosurgery, Department of SurgeryUniversity of Toronto, Toronto, ON, Canada
| | - Matthew W T Curran
- Division of Plastic and Reconstructive Surgery, Department of Surgery, University of Alberta, Edmonton, AB, Canada
| | - Jaret L Olson
- Division of Plastic and Reconstructive Surgery, Department of Surgery, University of Alberta, Edmonton, AB, Canada
| | - Michael J Morhart
- Division of Plastic and Reconstructive Surgery, Department of Surgery, University of Alberta, Edmonton, AB, Canada
| | - Line Jacques
- Division of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, CA, USA
| | - K Ming Chan
- Division of Physical Medicine and Rehabilitation, Department of Medicine, University of Alberta, Edmonton, AB, Canada
| |
Collapse
|
2
|
Budden C, Platt A, Jack A, Moulton R, Olson J, Mehta V. Peripheral nerve surgical competency in plastic surgery and neurosurgery residents. Clin Neurol Neurosurg 2022; 216:107217. [PMID: 35339861 DOI: 10.1016/j.clineuro.2022.107217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2022] [Revised: 03/15/2022] [Accepted: 03/18/2022] [Indexed: 11/19/2022]
Abstract
OBJECTIVE To assess the case volume and self-perceived competence of current mandatory skills in peripheral nerve surgery. DESIGN Cross sectional survey based study examining case volume and self-reported competence in peripheral nerve surgery. SETTING Canadian Neurosurgery and Plastic Surgery accredited residency programs PARTICIPANTS: All Canadian Neurosurgery and Plastic Surgery senior trainees (PGY 3+) invited to participate RESULTS: Much variability exists in both exposure to cases and perceived senior resident competence for both plastic and neurosurgery residents. Confidence in surgical ability as perceived competency is lower in trainees for more advanced peripheral nerve procedures. Self- reported confidence increased with post-graduate experience. CONCLUSIONS Overall, the findings in this study highlight the importance of increasing operative experience in complex peripheral nerve surgery among surgical residents.
Collapse
Affiliation(s)
- Curtis Budden
- Division of Plastic and Reconstructive Surgery, University of Alberta, Canada.
| | - Alexander Platt
- Faculty of Medicine and Dentistry, University of Alberta, Canada
| | - Andrew Jack
- Division of Neurosurgery, University of Alberta, Canada
| | - Rick Moulton
- Division of Neurosurgery, University of Ottawa, Canada
| | - Jaret Olson
- Division of Plastic and Reconstructive Surgery, University of Alberta, Canada
| | - Vivek Mehta
- Division of Neurosurgery, University of Alberta, Canada
| |
Collapse
|
3
|
Balas M, Prömmel P, Nguyen L, Jack A, Lebovic G, Badhiwala JH, Da Costa L, Nathens AB, Fehlings MG, Wilson JR, Witiw CD. The Reality of Accomplishing Surgery Within 24 hours for Complete Cervical Spinal Cord Injury: Clinical Practices and Safety. J Neurotrauma 2021; 38:3011-3019. [PMID: 34382411 DOI: 10.1089/neu.2021.0177] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Substantial clinical data supports an association between superior neurological outcomes and early (within 24 hours) surgical decompression for those with traumatic cervical spinal cord injury (SCI). Despite this, much discussion persists around feasibility and safety of this time threshold, particularly for those with a complete cervical SCI. This study aims to assess clinical practices and the safety profile of early surgery across a large sample of North American trauma centers. Data was derived from the Trauma Quality Improvement Program database from 2010-2016. Adult patients with a complete cervical SCI (ASIA A) who underwent surgery were included. Patients were stratified into those receiving surgery at or before 24 hours and those receiving delayed intervention. Risk-adjusted variability in surgical timing across trauma centers was investigated using mixed-effects regression. In-hospital adverse events including mortality, major complications, and immobility-related complications were compared between groups after propensity score matching. 2,862 patients from 353 North American trauma centers were included. 1,760 (61.5%) underwent surgery within 24 hours. Case-mix and hospital-level characteristics explained only 6% of the variability in surgical timing both between-centers and within-centers. No significant differences in adverse events were identified between groups. These findings suggest a relatively large proportion of patients are not receiving surgery within the recommended timeframe, despite apparent safety. Moreover, patient and hospital-level characteristics explain little of the variability in time-to-surgery. Further knowledge translation is needed to increase the proportion of patients in whom surgery is performed before the 24-hour threshold so patients might reach their greatest potential for neurologic recovery.
Collapse
Affiliation(s)
- Michael Balas
- University of Toronto, 7938, Division of Neurosurgery, Department of Surgery, 27 King's College Cirle, Toronto, Ontario, Canada, M5S;
| | - Peter Prömmel
- University of Toronto, 7938, Division of Neurosurgery, Department of Surgery, Toronto, Ontario, Canada.,Kantonsspital St Gallen, 30883, Department of Neurosurgery, Sankt Gallen, SG, Switzerland;
| | - Laura Nguyen
- University of Ottawa, 6363, School of Medicine, Ottawa, Ontario, Canada;
| | - Andrew Jack
- University of California San Francisco, 8785, Neurological Surgery, 400 Parnassus Ave, San Francisco, California, United States, 94143;
| | - Gerald Lebovic
- St Michael's Hospital Li Ka Shing Knowledge Institute, 518773, Toronto, Ontario, Canada.,University of Toronto Institute of Health Policy Management and Evaluation, 206712, Toronto, Ontario, Canada;
| | - Jetan H Badhiwala
- University of Toronto, 7938, Division of Neurosurgery, Department of Surgery, Toronto, Ontario, Canada;
| | - Leodante Da Costa
- University of Toronto, 7938, Division of Neurosurgery, Department of Surgery, Toronto, Ontario, Canada.,Sunnybrook Health Sciences Centre, 71545, Sunnybrook Research Institute, Toronto, Ontario, Canada;
| | - Avery B Nathens
- Sunnybrook Health Sciences Centre, 71545, Sunnybrook Research Institute, Toronto, Ontario, Canada.,University of Toronto, 7938, Division of General Surgery, Department of Surgery, Toronto, Ontario, Canada.,American College of Surgeons, 2417, Medical Director, Trauma Quality Improvement Program, Chicago, Illinois, United States;
| | - Michael G Fehlings
- University of Toronto, 7938, Division of Neurosurgery, Department of Surgery, Toronto, Ontario, Canada.,Toronto Western Hospital, 26625, Spine Program, Krembil Brain Institute, Toronto, Ontario, Canada;
| | - Jefferson R Wilson
- St Michael's Hospital, 10071, Division of Neurosurgery, Toronto, Ontario, Canada.,St Michael's Hospital, 10071, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada.,University of Toronto, 7938, Institute of Health Policy Management and Evaluation, Toronto, Ontario, Canada;
| | - Christopher D Witiw
- University of Toronto, 7938, Division of Neurosurgery, Department of Surgery, Toronto, Ontario, Canada.,St Michael's Hospital, 10071, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada.,University of Toronto, 7938, Institute of Health Policy Management and Evaluation, Toronto, Ontario, Canada;
| |
Collapse
|
4
|
Ramey WL, von Glinski A, Jack A, Blecher R, Oskouian RJ, Chapman JR. Antibiotic-impregnated polymethylmethacrylate strut graft as a treatment of spinal osteomyelitis: case series and description of novel technique. J Neurosurg Spine 2020; 33:1-6. [PMID: 32384277 DOI: 10.3171/2020.3.spine191313] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2019] [Accepted: 03/06/2020] [Indexed: 11/06/2022]
Abstract
OBJECTIVE The surgical treatment of osteomyelitis and discitis of the spine often represents a challenging clinical entity for a multitude of reasons, including progression of infection despite debridement, development of spinal deformity and instability, bony destruction, and seeding of hardware. Despite advancement in spinal hardware and implantation techniques, these aforementioned challenges not uncommonly result in treatment failure, especially in instances of heavy disease burden with enough bony endplate destruction as to not allow support of a modern titanium cage implant. While antibiotic-infused polymethylmethacrylate (aPMMA) has been used in orthopedic surgery in joints of the extremities, its use has not been extensively described in the spine literature. Herein, the authors describe for the first time a series of patients treated with a novel surgical technique for the treatment of spinal osteomyelitis and discitis using aPMMA strut grafts with posterior segmental fusion. METHODS Over the course of 3 years, all patients with spinal osteomyelitis and discitis at a single institution were identified and included in the retrospective cohort if they were surgically treated with spinal fusion and implantation of an aPMMA strut graft at the nidus of infection. Basic demographics, surgical techniques, levels treated, complications, and return to the operating room for removal of the aPMMA strut graft and placement of a traditional cage were examined. The surgical technique consisted of performing a discectomy and/or corpectomy at the level of osteomyelitis and discitis followed by placement of aPMMA impregnated with vancomycin and/or tobramycin into the cavity. Depending on the patient's condition during follow-up and other deciding clinical and radiographic factors, the patient may return to the operating room nonurgently for removal of the PMMA spacer and implantation of a permanent cage with allograft to ultimately promote fusion. RESULTS Fifteen patients were identified who were treated with an aPMMA strut graft for spinal osteomyelitis and discitis. Of these, 9 patients returned to the operating room for aPMMA strut graft removal and insertion of a cage with allograft at an average of 19 weeks following the index procedure. The most common infections were methicillin-sensitive Staphylococcus aureus (n = 6) and methicillin-resistant S. aureus (n = 5). There were 13 lumbosacral infections and 1 each of cervical and thoracic infection. Eleven patients were cured of their infection, while 2 had recurrence of their infection; 2 patients were lost to follow-up. Three patients required unplanned return trips to the operating room, two of which were for wound complications, with the third being for recurrent infection. CONCLUSIONS In cases of severe infection with considerable bony destruction, insertion of an aPMMA strut graft is a novel technique that should be considered in order to provide strong anterior-column support while directly delivering antibiotics to the infection bed. While the active infection is being treated medically, this structural aPMMA support bridges the time it takes for the patient to be converted from a catabolic to an anabolic state, when it is ultimately safe to perform a definitive, curative fusion surgery.
Collapse
Affiliation(s)
- Wyatt L Ramey
- 1Swedish Neuroscience Institute, Swedish Medical Center, Seattle
| | - Alexander von Glinski
- 1Swedish Neuroscience Institute, Swedish Medical Center, Seattle
- 2Seattle Science Foundation, Seattle, Washington
- 3Department of Trauma Surgery, BG University Hospital Bergmannsheil, Ruhr University Bochum, Germany; and
- 4Hansjoerg Wyss Hip and Pelvic Center, Swedish Hospital, Seattle, Washington
| | - Andrew Jack
- 1Swedish Neuroscience Institute, Swedish Medical Center, Seattle
| | - Ronen Blecher
- 1Swedish Neuroscience Institute, Swedish Medical Center, Seattle
| | - Rod J Oskouian
- 1Swedish Neuroscience Institute, Swedish Medical Center, Seattle
- 2Seattle Science Foundation, Seattle, Washington
| | - Jens R Chapman
- 1Swedish Neuroscience Institute, Swedish Medical Center, Seattle
| |
Collapse
|
5
|
von Glinski A, Yilmaz E, Ishak B, Hayman E, Ramey W, Jack A, Iwanaga J, Oskouian RJ, Tubbs RS, Chapman JR. The Modified Iliac Screw: An Anatomic Comparison and Technical Guide. World Neurosurg 2020; 136:e608-e613. [DOI: 10.1016/j.wneu.2020.01.091] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Revised: 01/11/2020] [Accepted: 01/13/2020] [Indexed: 11/25/2022]
|
6
|
Jack A, Ramey WL, Dettori JR, Tymchak ZA, Oskouian RJ, Hart RA, Chapman JR, Riew D. Factors Associated With C5 Palsy Following Cervical Spine Surgery: A Systematic Review. Global Spine J 2019; 9:881-894. [PMID: 31819855 PMCID: PMC6882094 DOI: 10.1177/2192568219874771] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
STUDY DESIGN Systematic review. OBJECTIVES C5 palsy (C5P) is a not uncommon and disabling postoperative complication with a reported incidence varying between 0% and 30%. Among others, one explanation for its occurrence includes foraminal nerve root tethering. Although different risk factors have been reported, controversy about its causation and prevention persists. Inconsistent study findings contribute to the persistent ambiguity leading to an assumption of a multifactorial nature of the underlying C5P pathophysiology. Here, we report the results of a systematic review on C5P with narrow inclusion criteria in the hope of elucidating risk factors for C5P due to a common pathophysiological mechanism. METHODS Electronic databases from inception to March 9, 2019 and references of articles were searched. Narrow inclusion criteria were applied to identify studies investigating demographic, clinical, surgical, and radiographic factors associated with postoperative C5P. RESULTS Sixteen studies were included after initial screening of 122 studies. Eighty-four risk factors were analyzed; 27 in ≥2 studies and 57 in single studies. The pooled prevalence of C5P was 6.0% (range: 4.2%-24.1%) with no consistent evidence that C5P was associated with demographic, clinical, or specific surgical factors. Of the radiographic factors assessed, specifically decreased foraminal diameter and preoperative cord rotation were identified as risk factors for C5P. CONCLUSION Although risk factors for C5P have been reported, ambiguity remains due to potentially multifactorial pathophysiology and study heterogeneity. We found foraminal diameter and cord rotation to be associated with postoperative C5P occurrence in our meta-analysis. These findings support the notion that factors contributing to, and acting synergistically with foraminal stenosis increase the risk of postoperative C5P.
Collapse
Affiliation(s)
- Andrew Jack
- Swedish Neuroscience Institute (SNI), Seattle, WA, USA,Andrew Jack, Swedish Neuroscience Institute, Cherry Hill Swedish Medical Center, Seattle, WA 98122, USA.
| | | | | | | | - Rod J. Oskouian
- Swedish Neuroscience Institute (SNI), Seattle, WA, USA,Spectrum Research, Inc, Steilacoom, WA, USA
| | | | | | - Dan Riew
- Columbia University Medical Center, The Spine Hospital at New York Presbyterian, New York, NY, USA
| |
Collapse
|
7
|
Kickbusch I, Agrawal A, Jack A, Lee N, Horton R. Governing health futures 2030: growing up in a digital world-a joint The Lancet and Financial Times Commission. Lancet 2019; 394:1309. [PMID: 31548090 DOI: 10.1016/s0140-6736(19)32181-6] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2019] [Accepted: 09/19/2019] [Indexed: 11/19/2022]
Affiliation(s)
- Ilona Kickbusch
- Global Health Centre, Graduate Institute of International and Development Studies, Geneva GE 1211, Switzerland.
| | - Anurag Agrawal
- CSIR-Institute of Genomics and Integrative Biology, New Delhi, India
| | | | | | | |
Collapse
|
8
|
Finucane S, Haridas S, Handley L, Clark J, Jack A, Munksted S. Known and unknown gene fusion detection capabilities of solid tumour laboratories conducting next generation sequencing in 6 countries. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz257.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Ramey WL, Altafulla J, Yilmaz E, Ishak B, Jack A, Litvack ZN, Oskouian RJ, Tubbs RS, Chapman JR. The ABC's of Spinal Decompression: Pearls and Technical Notes. World Neurosurg 2019; 129:e146-e151. [PMID: 31102772 DOI: 10.1016/j.wneu.2019.05.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2019] [Revised: 05/06/2019] [Accepted: 05/07/2019] [Indexed: 11/17/2022]
Abstract
OBJECTIVE The foundation of spine surgery centers on the proper identification, decompression, and stabilization of bony and neural elements. We describe easily reproducible and reliable methods for optimal decompression and release of neural structures to alleviate symptoms and improve patients' quality of life. METHODS Multiple spinal decompression techniques were described in procedures for which the goal of surgery was decompression alone or decompression and fusion. Eight fundamental techniques were described: inverted U-cut, J-cut, T-cut, L-cut, Z-cut, I-track cuts, C-cut, and O-cut. RESULTS These foundational cuts may be combined, as needed, to develop an individually tailored approach to the patient's pathology. CONCLUSIONS After properly identifying the anatomic structures, each of these techniques provides a consistent, reproducible, and efficient means to decompress the spine under various circumstances. These techniques provide surgical trainees with a framework for approaching surgical decompression.
Collapse
Affiliation(s)
- Wyatt L Ramey
- Department of Neurosurgery, Swedish Neuroscience Institute, Swedish Medical Center, Seattle, Washington, USA
| | - Juan Altafulla
- Department of Neuroanatomy, Seattle Science Foundation, Seattle, Washington, USA; Department of Neurosurgery, Swedish Neuroscience Institute, Swedish Medical Center, Seattle, Washington, USA
| | - Emre Yilmaz
- Department of Neuroanatomy, Seattle Science Foundation, Seattle, Washington, USA; Department of Neurosurgery, Swedish Neuroscience Institute, Swedish Medical Center, Seattle, Washington, USA
| | - Basem Ishak
- Department of Neuroanatomy, Seattle Science Foundation, Seattle, Washington, USA; Department of Neurosurgery, Swedish Neuroscience Institute, Swedish Medical Center, Seattle, Washington, USA
| | - Andrew Jack
- Department of Neurosurgery, Swedish Neuroscience Institute, Swedish Medical Center, Seattle, Washington, USA
| | - Zachary N Litvack
- Department of Neuroanatomy, Seattle Science Foundation, Seattle, Washington, USA; Department of Neurosurgery, Swedish Neuroscience Institute, Swedish Medical Center, Seattle, Washington, USA
| | - Rod J Oskouian
- Department of Neuroanatomy, Seattle Science Foundation, Seattle, Washington, USA; Department of Neurosurgery, Swedish Neuroscience Institute, Swedish Medical Center, Seattle, Washington, USA
| | - R Shane Tubbs
- Department of Neuroanatomy, Seattle Science Foundation, Seattle, Washington, USA; Department of Anatomical Sciences, St. George's University, St. George's, Grenada, West Indies
| | - Jens R Chapman
- Department of Neurosurgery, Swedish Neuroscience Institute, Swedish Medical Center, Seattle, Washington, USA.
| |
Collapse
|
10
|
Gleeson M, Counsell N, Cunningham D, Chadwick N, Lawrie A, Hawkes EA, McMillan A, Ardeshna KM, Jack A, Smith P, Mouncey P, Pocock C, Radford JA, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. Ann Oncol 2018; 28:2511-2516. [PMID: 28961838 PMCID: PMC5834096 DOI: 10.1093/annonc/mdx353] [Citation(s) in RCA: 57] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Background Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is associated with a dismal prognosis. Here, we report an analysis of CNS relapse for patients treated within the UK NCRI phase III R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) 14 versus 21 randomised trial. Patients and methods The R-CHOP 14 versus 21 trial compared R-CHOP administered two- versus three weekly in previously untreated patients aged ≥18 years with bulky stage I–IV DLBCL (n = 1080). Details of CNS prophylaxis were retrospectively collected from participating sites. The incidence and risk factors for CNS relapse including application of the CNS-IPI were evaluated. Results 177/984 patients (18.0%) received prophylaxis (intrathecal (IT) methotrexate (MTX) n = 163, intravenous (IV) MTX n = 2, prophylaxis type unknown n = 11 and IT MTX and cytarabine n = 1). At a median follow-up of 6.5 years, 21 cases of CNS relapse (isolated n = 11, with systemic relapse n = 10) were observed, with a cumulative incidence of 1.9%. For patients selected to receive prophylaxis, the incidence was 2.8%. Relapses predominantly involved the brain parenchyma (81.0%) and isolated leptomeningeal involvement was rare (14.3%). Univariable analysis demonstrated the following risk factors for CNS relapse: performance status 2, elevated lactate dehydrogenase, IPI, >1 extranodal site of disease and presence of a ‘high-risk’ extranodal site. Due to the low number of events no factor remained significant in multivariate analysis. Application of the CNS-IPI revealed a high-risk group (4-6 risk factors) with a 2- and 5-year incidence of CNS relapse of 5.2% and 6.8%, respectively. Conclusion Despite very limited use of IV MTX as prophylaxis, the incidence of CNS relapse following R-CHOP was very low (1.9%) confirming the reduced incidence in the rituximab era. The CNS-IPI identified patients at highest risk for CNS recurrence. ClinicalTrials.gov ISCRTN number 16017947 (R-CHOP14v21); EudraCT number 2004-002197-34.
Collapse
Affiliation(s)
- M Gleeson
- Department of Medicine, The Royal Marsden Hospital, London and Surrey, UK
| | - N Counsell
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - D Cunningham
- Department of Medicine, The Royal Marsden Hospital, London and Surrey, UK;.
| | - N Chadwick
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - A Lawrie
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - E A Hawkes
- Department of Oncology and Clinical Haematology, Austin Health, Heidelberg, Melbourne, Australia;; Department of Medical Oncology, Eastern Health, Melbourne, Australia
| | - A McMillan
- Department of Haematology, Nottingham City Hospital, Nottingham, UK
| | - K M Ardeshna
- Department of Haematology, University College London, London, UK;; Department of Haematology, Mount Vernon Cancer Centre, Northwood, UK
| | - A Jack
- HMDS, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - P Smith
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - P Mouncey
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - C Pocock
- Department of Haematology, East Kent Hospitals, Canterbury, UK
| | - J A Radford
- The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | - J Davies
- Department of Haematology, Western General Hospital, Edinburgh, UK
| | - D Turner
- Department of Haematology, Torbay Hospital, Torquay, UK
| | - A Kruger
- Department of Haematology, Royal Cornwall Hospital, Truro, UK
| | - P Johnson
- Cancer Research UK Centre, Southampton, UK
| | - J Gambell
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - D Linch
- Department of Haematology, University College London, London, UK
| |
Collapse
|
11
|
Eldirdiri S, Lee J, Jack A, Wright A, Findlay A, Phillips G. Outbreak of gentamicin-resistant, meticillin-susceptible Staphlococcus aureus on a neonatal unit. J Hosp Infect 2018; 98:419-424. [DOI: 10.1016/j.jhin.2017.11.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2017] [Accepted: 11/13/2017] [Indexed: 11/15/2022]
|
12
|
Adkins BD, Barlow AB, Jack A, Schultenover SJ, Desouki MM, Coogan AC, Weiss VL. Characteristic findings of cervical Papanicolaou tests from transgender patients on androgen therapy: Challenges in detecting dysplasia. Cytopathology 2018; 29:281-287. [PMID: 29488269 DOI: 10.1111/cyt.12525] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/24/2017] [Indexed: 11/27/2022]
Abstract
INTRODUCTION The characteristic features of Papanicolaou (Pap) tests collected from female-to-male (FTM) transgender patients on androgen therapy have not been well defined in the literature. FTM transgender patients require cervical cancer screening with the same recommended frequency as cis-gender females. Dysplasia remains challenging to differentiate from atrophy. Without pertinent history, the atrophic findings in younger transgender patients can be misinterpreted as high-grade dysplasia. METHODS A review of all cervical Pap tests of transgender patients receiving androgen therapy (2010-2017) was performed. Bethesda diagnosis, cytomorphological features, HPV testing and cervical biopsy results were reviewed. RESULTS Eleven transgender patients receiving androgen therapy were identified with 23 cervical Pap tests, 11 HPV tests and five cervical biopsies performed. A review of the Pap tests demonstrated: 57% negative for intraepithelial lesion; 13% unsatisfactory; 13% atypical squamous cells of undetermined significance; 13% atypical squamous cells - cannot exclude high-grade squamous intraepithelial lesion; and 4% high-grade squamous intraepithelial lesion. The rates of abnormal tests were higher than our age-matched cis-gender atrophic cohort rates of unsatisfactory (0.5%), atypical squamous cells of undetermined significance (7%), atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (0%) and high-grade squamous intraepithelial lesion (0.5%). The cytological findings from liquid-based preparations included dispersed and clustered parabasal-type cells, scattered degenerated cells, smooth evenly dispersed chromatin, and occasional mild nuclear enlargement and irregularity. Dysplastic cells had larger nuclei, hyperchromatic clumped chromatin, and more irregular nuclear contours. CONCLUSIONS The evaluation of dysplasia can be challenging on Pap tests from transgender patients on androgen therapy. The cohort evaluated had higher rates of unsatisfactory and abnormal Pap tests. Pathologists should be familiar with the distinctive cytomorphological changes in the Pap tests from patients on androgen therapy to evaluate them appropriately.
Collapse
Affiliation(s)
- B D Adkins
- Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA
| | - A B Barlow
- Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN, USA
| | - A Jack
- Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA
| | - S J Schultenover
- Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA
| | - M M Desouki
- Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA
| | - A C Coogan
- Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA
| | - V L Weiss
- Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA
| |
Collapse
|
13
|
Chuang ST, Liu WB, Chou CC, Jack A, Chan JPW. Corpus luteum graviditatis with a follicular lutein cyst-like structure during early pregnancy in a cow. Tierarztl Prax Ausg G Grosstiere Nutztiere 2018. [DOI: 10.1055/s-0038-1623981] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
14
|
Kühnl A, Cunningham D, Counsell N, Hawkes EA, Qian W, Smith P, Chadwick N, Lawrie A, Mouncey P, Jack A, Pocock C, Ardeshna KM, Radford J, McMillan A, Davies J, Turner D, Kruger A, Johnson PW, Gambell J, Rosenwald A, Ott G, Horn H, Ziepert M, Pfreundschuh M, Linch D. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial. Ann Oncol 2017; 28:1540-1546. [PMID: 28398499 PMCID: PMC5815562 DOI: 10.1093/annonc/mdx128] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2016] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND There is an on-going debate whether 2- or 3-weekly administration of R-CHOP is the preferred first-line treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL). The UK NCRI R-CHOP14v21 randomized phase 3 trial did not demonstrate a difference in outcomes between R-CHOP-14 and R-CHOP-21 in newly diagnosed DLBCL patients aged 19-88 years, but data on elderly patients have not been reported in detail so far. Here, we provide a subgroup analysis of patients ≥60 years treated on the R-CHOP14v21 trial with extended follow-up. PATIENTS AND METHODS Six hundred and four R-CHOP14v21 patients ≥60 years were included in this subgroup analysis, with a median follow-up of 77.7 months. To assess the impact of MYC rearrangements (MYC-R) and double-hit-lymphoma (DHL) on outcome in elderly patients, we performed a joint analysis of cases with available molecular data from the R-CHOP14v21 (N = 217) and RICOVER-60 (N = 204) trials. RESULTS Elderly DLBCL patients received high dose intensities with median total doses of ≥98% for all agents. Toxicities were similar in both arms with the exception of more grade ≥3 neutropenia (P < 0.0001) and fewer grade ≥3 thrombocytopenia (P = 0.05) in R-CHOP-21 versus R-CHOP-14. The elderly patient population had a favorable 5-year overall survival (OS) of 69% (95% CI: 65-73). We did not identify any subgroup of patients that showed differential response to either regimen. In multivariable analysis including individual factors of the IPI, gender, bulk, B2M and albumin levels, only age and B2M were of independent prognostic significance for OS. Molecular analyses demonstrated a significant impact of MYC-R (HR = 1.96; 95% CI: 1.22-3.16; P = 0.01) and DHL (HR = 2.21; 95% CI: 1.18-4.11; P = 0.01) on OS in the combined trial cohorts, independent of other prognostic factors. CONCLUSIONS Our data support equivalence of both R-CHOP application forms in elderly DLBCL patients. Elderly MYC-R and DHL patients have inferior prognosis and should be considered for alternative treatment approaches. TRIAL NUMBERS ISCRTN 16017947 (R-CHOP14v21); NCT00052936 (RICOVER-60).
Collapse
MESH Headings
- Age Factors
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Murine-Derived/administration & dosage
- Antibodies, Monoclonal, Murine-Derived/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Biomarkers, Tumor/genetics
- Cyclophosphamide/administration & dosage
- Cyclophosphamide/adverse effects
- Doxorubicin/administration & dosage
- Doxorubicin/adverse effects
- Drug Administration Schedule
- Female
- Gene Rearrangement
- Humans
- Kaplan-Meier Estimate
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/genetics
- Lymphoma, Large B-Cell, Diffuse/mortality
- Lymphoma, Large B-Cell, Diffuse/pathology
- Male
- Middle Aged
- Multivariate Analysis
- Patient Selection
- Precision Medicine
- Prednisone/administration & dosage
- Prednisone/adverse effects
- Proto-Oncogene Proteins c-bcl-2/genetics
- Proto-Oncogene Proteins c-bcl-6/genetics
- Proto-Oncogene Proteins c-myc/genetics
- Risk Factors
- Rituximab
- Time Factors
- Treatment Outcome
- United Kingdom
- Vincristine/administration & dosage
- Vincristine/adverse effects
Collapse
Affiliation(s)
- A. Kühnl
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
| | - D. Cunningham
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
| | - N. Counsell
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - E. A. Hawkes
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
- Olivia-Newton John Cancer Research & Wellness Centre, Melbourne, Australia
| | - W. Qian
- Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge
| | - P. Smith
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - N. Chadwick
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - A. Lawrie
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - P. Mouncey
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - A. Jack
- HMDS, St James’s Institute of Oncology, Leeds
| | | | - K. M. Ardeshna
- Department of Hematology, University College London, London
- Mount Vernon Cancer Centre, Northwood
| | - J. Radford
- Department of Medical Oncology, University of Manchester and the Christie NHS Foundation Trust, Manchester
| | - A. McMillan
- Department of Hematology, Nottingham City Hospital, Nottingham
| | | | - D. Turner
- Department of Hematology, Torbay Hospital, Torquay
| | | | - P. W. Johnson
- Cancer Research UK Center, University of Southampton, Southampton, UK
| | - J. Gambell
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - A. Rosenwald
- Institute of Pathology, Würzburg University, Würzburg
| | - G. Ott
- Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart
| | - H. Horn
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Stuttgart
| | - M. Ziepert
- Institute for Medical Informatics, Statistics, and Epidemiology, University of Leipzig, Leipzig
| | - M. Pfreundschuh
- Department of Medicine, Saarland University Medical School, Homburg/Saar, Germany
| | - D. Linch
- Department of Hematology, University College London, London
| |
Collapse
|
15
|
Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. J Clin Oncol 2017; 35:1905-1912. [PMID: 28355112 DOI: 10.1200/jco.2016.70.6994] [Citation(s) in RCA: 108] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Purpose There is no consensus on the optimal systemic treatment of patients with extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. The IELSG-19 phase III study, to our knowledge, was the first such study to address the question of first-line treatment in a randomized trial. Patients and Methods Eligible patients were initially randomly assigned (1:1 ratio) to receive either chlorambucil monotherapy (6 mg/m2/d orally on weeks 1 to 6, 9 to 10, 13 to 14, 17 to 18, and 21 to 22) or a combination of chlorambucil (same schedule as above) and rituximab (375 mg/m2 intravenously on day 1 of weeks 1, 2, 3, 4, 9, 13, 17, and 21). After the planned enrollment of 252 patients, the protocol was amended to continue with a three-arm design (1:1:6 ratio), with a new arm that included rituximab alone (same schedule as the combination arm) and with a final sample size of 454 patients. The main end point was event-free survival (EFS). Analysis of chlorambucil versus the combination arm was performed and reported separately before any analysis of the third arm. Results At a median follow-up of 7.4 years, addition of rituximab to chlorambucil led to significantly better EFS (hazard ratio, 0.54; 95% CI, 0.38 to 0.77). EFS at 5 years was 51% (95% CI, 42 to 60) with chlorambucil alone, 50% (95% CI, 42 to 59) with rituximab alone, and 68% (95% CI, 60 to 76) with the combination ( P = .0009). Progression-free survival was also significantly better with the combination ( P = .0119). Five-year overall survival was approximately 90% in each arm. All treatments were well tolerated. No unexpected toxicities were recorded. Conclusion Rituximab in combination with chlorambucil demonstrated superior efficacy in mucosa-associated lymphoid tissue lymphoma; however, improvements in EFS and progression-free survival did not translate into longer overall survival.
Collapse
Affiliation(s)
- Emanuele Zucca
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Annarita Conconi
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Giovanni Martinelli
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Reda Bouabdallah
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Alessandra Tucci
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Umberto Vitolo
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Maurizio Martelli
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Ruth Pettengell
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Gilles Salles
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Catherine Sebban
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Armando Lopez Guillermo
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Graziella Pinotti
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Liliana Devizzi
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Franck Morschhauser
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Hervé Tilly
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Valter Torri
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Stefan Hohaus
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Andrés J M Ferreri
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Pierre Zachée
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - André Bosly
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Corinne Haioun
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Caterina Stelitano
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Monica Bellei
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Maurilio Ponzoni
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Anne Moreau
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Andrew Jack
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Elias Campo
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Luca Mazzucchelli
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Franco Cavalli
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Peter Johnson
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| | - Catherine Thieblemont
- Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium
| |
Collapse
|
16
|
Davies A, Barrans S, Maishman T, Cummin T, Bentley M, Mamot C, Novak U, Caddy J, Hamid D, Kazmi-Stokes S, Mcmillan A, Fields P, Pocock C, Kruger A, Collins G, Sha C, Clipson A, Wang M, Tooze R, Care M, Griffiths G, Du M, Westhead D, Burton C, Jack A, Johnson P. DIFFERENTIAL EFFICACY OF BORTEZOMIB IN SUBTYPES OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBL): a PROSPECTIVE RANDOMISED STUDY STRATIFIED BY TRANSCRIPTOME PROFILING: REMODL-B. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_120] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A.J. Davies
- Cancer Research UK Centre; University of Southampton (PMAL Consortium); Southampton UK
| | - S. Barrans
- Haematological Malignancy Diagnostic Service, Haematological Malignancy Diagnostic Service; St. James's Institute of Oncology, Leeds; Leeds UK
| | - T. Maishman
- Southampton Clinical Trials Unit; University of Southampton; Southampton UK
| | - T.E. Cummin
- Cancer Research UK Centre; University of Southampton (PMAL Consortium); Southampton UK
| | - M. Bentley
- School of Molecular and Cellular Biology; University of Leeds; Leeds UK
| | - C. Mamot
- Swiss Group for Clinical Cancer Research (SAKK); Kantonsspital Aarau; Bern Switzerland
| | - U. Novak
- Swiss Group for Clinical Cancer Research (SAKK); Inselspital / Bern University Hospital; Bern Switzerland
| | - J. Caddy
- Cancer Research UK Centre; University of Southampton (PMAL Consortium); Southampton UK
| | - D. Hamid
- Southampton Clinical Trials Unit; University of Southampton; Southampton UK
| | - S.H. Kazmi-Stokes
- Cancer Research UK Centre; University of Southampton (PMAL Consortium); Southampton UK
| | - A. Mcmillan
- Haematology; Nottingham City Hospital; Nottingham UK
| | - P.A. Fields
- Haematology; Guy's and St Thomas' and King's College Hospitals; London UK
| | - C. Pocock
- Haematology; East Kent Hospitals University NHS Trust; Canterbury UK
| | - A. Kruger
- Haematology; Royal Cornwall Hospital; Truro UK
| | - G. Collins
- Clinical Haematology; Churchill Hospital; Oxford UK
| | - C. Sha
- Bioinformatics group, IMCB; University of Leeds; Leeds UK
| | - A. Clipson
- Division of Molecular Histopathology; University of Cambridge; Cambridge UK
| | - M. Wang
- Division of Molecular Histopathology; University of Cambridge; Cambridge UK
| | - R.M. Tooze
- Faculty of Medicine and Health; University of Leeds; Leeds UK
| | - M.A. Care
- Faculty of Medicine and Health; University of Leeds; Leeds UK
| | - G.O. Griffiths
- Southampton Clinical Trials Unit; University of Southampton; Southampton UK
| | - M. Du
- Division of Molecular Histopathology; University of Cambridge; Cambridge UK
| | - D.R. Westhead
- School of Molecular and Cellular Biology; University of Leeds; Leeds UK
| | - C. Burton
- Haematological Malignancy Diagnostic Service, Haematological Malignancy Diagnostic Service; St. James's Institute of Oncology, Leeds; Leeds UK
| | - A. Jack
- Haematological Malignancy Diagnostic Service, Haematological Malignancy Diagnostic Service; St. James's Institute of Oncology, Leeds; Leeds UK
| | - P.W. Johnson
- Cancer Research UK Centre; University of Southampton (PMAL Consortium); Southampton UK
| |
Collapse
|
17
|
Burton C, Sha C, Barrans S, Jack A, Painter D, Smith A, Roman E, Crouch S, Care M, Tooze R, Westhead D. A category-free approach to prognostic modelling in aggressive non-Hodgkin B cell lymphomas based on large patient databases. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_70] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- C. Burton
- Leeds Cancer Centre; Haematology Malignancy Diagnostic Service; Leeds UK
| | - C. Sha
- University of Leeds; Institute of Molecular and Cellular Biology; Leeds UK
| | - S. Barrans
- Leeds Cancer Centre; Haematology Malignancy Diagnostic Service; Leeds UK
| | - A. Jack
- Leeds Cancer Centre; Haematology Malignancy Diagnostic Service; Leeds UK
| | - D. Painter
- University of York; Epidemiology and Cancer Statistics Group; York UK
| | - A. Smith
- University of York; Epidemiology and Cancer Statistics Group; York UK
| | - E. Roman
- University of York; Epidemiology and Cancer Statistics Group; York UK
| | - S. Crouch
- University of York; Epidemiology and Cancer Statistics Group; York UK
| | - M. Care
- University of Leeds; Leeds Institute of Cancer and Pathology; Leeds UK
| | - R. Tooze
- University of Leeds; Leeds Institute of Cancer and Pathology; Leeds UK
| | - D. Westhead
- University of Leeds; Institute of Molecular and Cellular Biology; Leeds UK
| |
Collapse
|
18
|
McDougall CM, Khan K, Saqqur M, Jack A, Rempel J, Derksen C, Xi Y, Chow M. Ultrasound for the evaluation of stenosis after flow diversion. J Neurointerv Surg 2017; 10:297-300. [DOI: 10.1136/neurintsurg-2017-013049] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2017] [Revised: 04/10/2017] [Accepted: 04/22/2017] [Indexed: 11/03/2022]
Abstract
Background and purposeFlow diversion is a relatively new strategy used to treat complex cerebral aneurysms. The optimal method for radiographic follow-up of patients treated with flow diverters has not been established. The rate and clinical implications of in-stent stenosis for these devices is unclear. We evaluate the use of transcranial Doppler ultrasound (TCD) for follow-up of in-stent stenosis.Materials and methodsWe analyzed 28 patients treated with the Pipeline embolization device (PED) over the course of 42 months from January 2009 to June 2012. Standard conventional cerebral angiograms were performed in all patients. TCD studies were available in 23 patients.ResultsAngiographic and TCD results were compared and found to correlate well.ConclusionsTCD is a potentially useful adjunct for evaluating in-stent stenosis after flow diversion.
Collapse
|
19
|
Stevens WBC, Mendeville M, Redd R, Clear AJ, Bladergroen R, Calaminici M, Rosenwald A, Hoster E, Hiddemann W, Gaulard P, Xerri L, Salles G, Klapper W, Pfreundschuh M, Jack A, Gascoyne RD, Natkunam Y, Advani R, Kimby E, Sander B, Sehn LH, Hagenbeek A, Raemaekers J, Gribben J, Kersten MJ, Ylstra B, Weller E, de Jong D. Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. Haematologica 2017; 102:1413-1423. [PMID: 28411252 PMCID: PMC6643731 DOI: 10.3324/haematol.2017.165415] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2017] [Accepted: 04/11/2017] [Indexed: 01/25/2023] Open
Abstract
In follicular lymphoma, studies addressing the prognostic value of microenvironment-related immunohistochemical markers and tumor cell-related genetic markers have yielded conflicting results, precluding implementation in practice. Therefore, the Lunenburg Lymphoma Biomarker Consortium performed a validation study evaluating published markers. To maximize sensitivity, an end of spectrum design was applied for 122 uniformly immunochemotherapy-treated follicular lymphoma patients retrieved from international trials and registries. The criteria were: early failure, progression or lymphoma-related death <2 years versus long remission, response duration of >5 years. Immunohistochemical staining for T cells and macrophages was performed on tissue microarrays from initial biopsies and scored with a validated computer-assisted protocol. Shallow whole-genome and deep targeted sequencing was performed on the same samples. The 96/122 cases with complete molecular and immunohistochemical data were included in the analysis. EZH2 wild-type (P=0.006), gain of chromosome 18 (P=0.002), low percentages of CD8+ cells (P=0.011) and CD163+ areas (P=0.038) were associated with early failure. No significant differences in other markers were observed, thereby refuting previous claims of their prognostic significance. Using an optimized study design, this Lunenburg Lymphoma Biomarker Consortium study substantiates wild-type EZH2 status, gain of chromosome 18, low percentages of CD8+ cells and CD163+ area as predictors of early failure to immunochemotherapy in follicular lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP [-like]), while refuting the prognostic impact of various other markers.
Collapse
Affiliation(s)
| | - Matias Mendeville
- Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands
| | - Robert Redd
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - Andrew J Clear
- Centre for Haemato-Oncology, Barts Cancer Institute, University of London, UK
| | - Reno Bladergroen
- Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands
| | - Maria Calaminici
- Centre for Haemato-Oncology, Barts Cancer Institute, University of London, UK
| | - Andreas Rosenwald
- Institute of Pathology, Comprehensive Cancer Center Mainfranken, University of Würzburg, Germany
| | - Eva Hoster
- Department of Medicine III, University Hospital Grosshadern, Munich, Germany
| | - Wolfgang Hiddemann
- Department of Medicine III, University Hospital Grosshadern, Munich, Germany
| | - Philippe Gaulard
- Department of Pathology and Inserm U955, Hôpital Henri Mondor, University Paris-Est, Créteil, France
| | - Luc Xerri
- Département de Biopathologie, Institut Paoli-Calmettes, Marseille, France
| | - Gilles Salles
- Service d'Hématologie,Hospices Civils de Lyon & Université Claude Bernard Lyon-1, UMR CNRS 5239, France
| | - Wolfram Klapper
- Institute of Pathology, University of Schleswig-Holstein, Kiel, Germany
| | | | - Andrew Jack
- Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, UK
| | - Randy D Gascoyne
- Department of Pathology & Medical Oncology, Centre for Lymphoid Cancer, British Columbia Cancer Agency, University of British Columbia, Vancouver, Canada
| | - Yasodha Natkunam
- Department of Pathology, Stanford University School of Medicine, CA, USA
| | - Ranjana Advani
- Department of Hematology, Stanford University School of Medicine, CA, USA
| | - Eva Kimby
- Department of Medicine, Division of Hematology, Karolinska Institute, Stockholm, Sweden
| | - Birgitta Sander
- Department of Laboratory Medicine, Division of Pathology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden
| | - Laurie H Sehn
- Department of Pathology & Medical Oncology, Centre for Lymphoid Cancer, British Columbia Cancer Agency, University of British Columbia, Vancouver, Canada
| | - Anton Hagenbeek
- Department of Hematology, Academic Medical Center, Amsterdam, the Netherlands
| | - John Raemaekers
- Department of Hematology, Radboudumc, Nijmegen, the Netherlands
| | - John Gribben
- Centre for Haemato-Oncology, Barts Cancer Institute, University of London, UK
| | - Marie José Kersten
- Department of Hematology, Academic Medical Center, Amsterdam, the Netherlands
| | - Bauke Ylstra
- Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands
| | - Edie Weller
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - Daphne de Jong
- Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands
| |
Collapse
|
20
|
Snowden JA, O'Connell S, Hawkins J, Dalley C, Jack A, Mannari D, McNamara C, Scott M, Shenton G, Soilleux E, Macbeth F. Haematological cancers: improving outcomes. A summary of updated NICE service guidance in relation to Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS). J Clin Pathol 2017; 70:461-468. [PMID: 28389440 DOI: 10.1136/jclinpath-2016-204029] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2017] [Revised: 02/13/2017] [Accepted: 02/14/2017] [Indexed: 11/04/2022]
Abstract
Haematological malignancies are a diverse group of cancers that affect the blood, bone marrow and lymphatic systems. Laboratory diagnosis of haematological malignancies is dependent on combining several technologies, including morphology, immunophenotyping, cytogenetics and molecular genetics correlated clinical details and classification according to the current WHO guidelines. The concept of the Specialised Integrated Haematological Malignancy Diagnostic Services (SIHMDS) has evolved since the UK National Institute for Health and Care Excellence (NICE) Improving Outcomes Guidance (IOG) in 2003 and subsequently various models of delivery have been established. As part of the 2016 update to the NICE IOG, these models were systematically evaluated and recommendations produced to form the basis for quality standards for future development of SIHMDS. We provide a summary of the systematic review and recommendations. Although the recommendations pertain to the UK National Health Service (NHS), they have relevance to the modern delivery of diagnostic services internationally.
Collapse
Affiliation(s)
- John A Snowden
- Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK
| | - Susan O'Connell
- Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK
| | - James Hawkins
- Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK
| | - Chris Dalley
- Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK
| | - Andrew Jack
- Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK
| | - Deepak Mannari
- Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK
| | - Chris McNamara
- Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK
| | - Mike Scott
- Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK
| | - Geoff Shenton
- Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK
| | - Elizabeth Soilleux
- Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK
| | - Fergus Macbeth
- Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK
| | | |
Collapse
|
21
|
Jack A, Hardy-St-Pierre G, Wilson M, Choy G, Fox R, Nataraj A. Anterior Surgical Fixation for Cervical Spine Flexion-Distraction Injuries. World Neurosurg 2017; 101:365-371. [PMID: 28213193 DOI: 10.1016/j.wneu.2017.02.027] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2016] [Revised: 02/04/2017] [Accepted: 02/06/2017] [Indexed: 12/31/2022]
Abstract
BACKGROUND Optimal surgical management for flexion-distraction cervical spine injuries remains controversial with current guidelines recommending anterior, posterior, and circumferential approaches. Here, we determined the incidence of and examined risk factors for clinical and radiographic failure in patients with 1-segment cervical distraction injuries having undergone anterior surgical fixation. METHODS A retrospective review of 57 consecutive patients undergoing anterior fixation for subaxial flexion-distraction cervical injuries between 2008 and 2012 at our institution was performed. The primary outcome was the number of patients requiring additional surgical stabilization and/or radiographic failure. Data collected included age, gender, mechanism and level of injury, facet pattern injury, and vertebral end plate fracture. RESULTS A total of 6 patients failed clinically and/or radiographically (11%). Four patients (7%) required additional posterior fixation. Although 2 other patients identified met radiographic failure criteria, at follow-up they had fused radiographically, were stable clinically, and no further treatment was pursued. Progressive kyphosis and translation were found to be significantly correlated with need for revision (P < 0.05 and P = 0.02, respectively). No differences were identified for all other clinical and radiologic factors assessed, including unilateral or bilateral facet injury, facet fracture, and end plate fracture. CONCLUSION This study contributes to the growing body of evidence supporting anterior fixation alone for flexion-distraction injuries. Findings suggest that current measurements of radiographic failure including segmental translation and kyphosis may predict radiographic failure and need for further surgical stabilization in some patients. Future follow-up studies assessing for independent risk factors for anterior approach failure with a validated predictive scoring model should be considered.
Collapse
Affiliation(s)
- Andrew Jack
- Division of Neurosurgery, Department of Surgery, University of Alberta Hospital, Edmonton, Alberta, Canada.
| | - Godefroy Hardy-St-Pierre
- Division of Neurosurgery, Department of Surgery, University of Alberta Hospital, Edmonton, Alberta, Canada
| | - Mitchell Wilson
- Department of Radiology and Diagnostic Imaging, University of Alberta Hospital, Edmonton, Alberta, Canada
| | - Godwin Choy
- Division of Neurosurgery, Department of Surgery, University of Alberta Hospital, Edmonton, Alberta, Canada
| | - Richard Fox
- Division of Neurosurgery, Department of Surgery, University of Alberta Hospital, Edmonton, Alberta, Canada
| | - Andrew Nataraj
- Division of Neurosurgery, Department of Surgery, University of Alberta Hospital, Edmonton, Alberta, Canada
| |
Collapse
|
22
|
Gleeson M, Hawkes EA, Cunningham D, Chadwick N, Counsell N, Lawrie A, Jack A, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford J, McMillan A, Davies J, Turner D, Kruger A, Johnson PWM, Gambell J, Linch D. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. Br J Haematol 2016; 175:668-672. [PMID: 27477167 DOI: 10.1111/bjh.14287] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2016] [Accepted: 06/22/2016] [Indexed: 11/30/2022]
Abstract
We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median follow-up of 7·2 years the 5-year progression-free survival and overall survival was 79·8% and 83·8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients.
Collapse
Affiliation(s)
- Mary Gleeson
- The Royal Marsden Hospital, London and Surrey, UK
| | - Eliza A Hawkes
- Department of Oncology and Clinical Haematology, Austin Health, Heidelberg, Melbourne, Australia
- Eastern Health, Melbourne, Australia
| | | | - Nick Chadwick
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - Nicholas Counsell
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - Anthony Lawrie
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - Andrew Jack
- HMDS, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Paul Smith
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - Paul Mouncey
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | | | - Kirit M Ardeshna
- University College London, London, UK
- Mount Vernon Cancer Centre, Northwood, UK
| | - John Radford
- The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | | | | | | | | | | | - Joanna Gambell
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | | |
Collapse
|
23
|
|
24
|
Engelhardt M, Hamad M, Patz S, Wirth M, Grabert J, König J, Jamann N, Jack A, di Cristo G, Maffei L, Berardi N, Wahle P. EP 86. Interneuron synaptopathy induced by the pro-inflammatory cytokine LIF in developing neocortex. Clin Neurophysiol 2016. [DOI: 10.1016/j.clinph.2016.05.136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
25
|
|
26
|
Aleem I, Xu Y, Rampersaud YR, Pahuta M, St-Pierre GH, Crawford E, Zarrabian M, St-Pierre GH, Yang M, Scheer J, St-Pierre GH, Lou E, Malleck S, Soroceanu A, Soroceanu A, White B, Holtz KA, Fallah N, Noonan V, Finkelstein J, Rivers C, Tee J, Paquet J, Rutges J, Martin AR, Martin AR, Jack A, Malakoutian M, Kwon B, St-Pierre GH, Nater A, Versteeg A, Pahuta M, Fenton E, Nagoshi N, Tetreault L, Witiw C, Santaguida C, Aziz M, Khashan M, Tomkins-Lane C, Miyanji F, Johnson M, Tee J, Roffey DM, Evaniew N, Nouri A, Tetreault L, Arnold P, Tetreault L, Fehlings M, Wilson J, Smith JS, Charest-Morin R, Charest-Morin R, Marion T, Marion T, Kato S, Miyanji F, Enright A, Daly E, Fehlings M, Dakson A, Dakson A, Leck E, Khashan M, Abraham E, Manson N, Pahuta M, Duncan J, Ahmed A, Eck J, Rhee J, Currier B, Nassr A, Yen D, Johnson A, Bidos A, Schultz S, Fanti C, Young B, Drew B, Puskas D, Henry D, Frombach A, Mitera G, Coyle D, Werier J, Wai E, Hurlbert J, Ravinsky R, Bidos A, Rampersaud YR, Bidos A, Fanti C, Young B, Drew B, Puskas D, Rampersaud R, Yang M, Hurlbert J, Thomas K, St-Pierre GH, Duplessis S, Ailon T, Smith J, Shaffrey C, Klineberg E, Schwab F, Ames C, Yang M, Hurlbert J, Thomas K, Nataraj A, Zheng R, Hill D, Moreau M, Hedden D, Southon S, Johnson M, Goytan M, Passmore S, McIntosh G, Smith J, Lafage V, Klineberg E, Ailon T, Ames C, Shaffrey C, Gupta M, Kebaish K, Scubbia D, Hart R, Hostin R, Schwab F, Kelly M, Smith J, Scheer J, Lafage V, Protopsaltis T, Lafage R, Hostin R, Kebaish K, Gupta M, Hart R, Schwab F, Ames C, Dea N, Street J, Dvorak M, Lipson R, Noonan VK, Kwon BK, Mills PB, Noonan V, Shum J, Rivers C, Street J, Park SE, Chan E, Plashkes T, Dvorak M, Fallah N, Bedi M, Chan E, Rivers C, Street J, Plashkes T, Dvorak M, Noonan V, Fallah N, Ho C, Tsai E, Rivers C, Truchon C, Linassi AG, O’Connell C, Townson A, Ahn H, Drew B, Dvorak M, Fehlings MG, Schwartz C, Noreau L, Warner F, Noonan V, Fallah N, Fisher C, O’Connell C, Tsai E, Ahn H, Attabib N, Christie S, Drew B, Finkelstein J, Fourney D, Paquet J, Parent S, Kuerban D, Dvorak M, Paquet J, Noonan V, Kwon B, Tsai E, Christie S, Rivers C, Kuerban D, Ahn H, Attabib N, Bailey C, Drew B, Fehlings M, Finkelstein J, Fourney D, Hurlbert RJ, Parent S, Fisher C, Dvorak M, Noonan V, Kwon B, Tsai E, Christie S, Rivers C, Ahn H, Attabib N, Bailey C, Drew B, Fehlings M, Finkelstein J, Fourney D, Hurlbert RJ, Parent S, Kuerban D, Dvorak M, Kwon B, Dvorak M, Aleksanderek I, Cohen-Adad J, Cadotte DW, Kalsi-Ryan S, De Leener B, Wang J, Crawley A, Mikulis DJ, Ginsberg H, Fehlings MG, Aleksanderek I, Cohen-Adad J, Tarmohamed Z, Tetreault L, Smith N, Cadotte DW, Crawley A, Ginsberg H, Mikulis DJ, Fehlings MG, Nataraj A, Fouad K, Street J, Wilke HJ, Stavness I, Dvorak M, Fels S, Oxland T, Streijger F, Fallah N, Noonan V, Paquette S, Boyd M, Ailon T, Street J, Fisher C, Dvorak M, Hurlbert J, Fehlings M, Tetreault L, Kopjar B, Arnold P, Dekutoski M, Finkelstein J, Fisher C, France J, Gokaslan Z, Massicotte E, Rhines L, Rose P, Sahgal A, Schuster J, Vaccaro A, Dea N, Boriani S, Varga PP, Luzzati A, Fehlings M, Bilsky M, Rhines L, Reynolds J, Dekutoski M, Gokaslan Z, Germscheid N, Fisher C, van Walraven C, Coyle D, Werier J, Wai E, Mercier P, Bains I, Jacobs WB, Tetreault L, Nakashima H, Nouri A, Fehlings M, Kopjar B, Wilson J, Arnold P, Fehlings M, Tetreault L, Kopjar B, Massicotte E, Fehlings M, Fehlings M, Kopjar B, Arnold P, Defino H, Kale S, Yoon ST, Barbagallo G, Bartels R, Zhou Q, Vaccaro A, Johnson M, Passmore S, Goytan M, Glazebrook C, Golan J, McIntosh G, Barker J, Weber M, Hu R, Norden J, Sinha A, Smuck M, Desai S, Samdani AF, Shah SA, Asghar J, Yaszay B, Shufflebarger HL, Betz RR, Newton P, Passmore S, McCammon J, Goytan M, McIntosh G, Fisher C, Alfasi A, Hashem EL, Papineau GD, Kingwell SP, Wai EK, Belley-Côté EP, Fallah N, Noonan VK, Rivers CS, Dvorak MF, Tetreault L, Dalzell K, Zamorano JJ, Fehlings M, Shamji M, Rhee J, Wilson J, Andersson I, Dembek A, Pagarigan K, Dettori J, Fehlings M, Kopjar B, Tetreault L, Nakashima H, Fehlings M, Kopjar B, Arnold P, Kotter M, Fehlings M, Wilson J, Arnold P, Shaffrey C, Shamji M, Mroz T, Skelly A, Chapman J, Tetreault L, Aarabi B, Casha S, Jaglal S, Voth J, Yee A, Fehlings M, Klineberg E, Shaffrey CI, Lafage V, Schwab FJ, Protopsaltis T, Scheer JK, Ailon T, Ramachandran S, Daniels A, Mundis G, Gupta M, Deviren V, Ames CP, Street J, Stobart L, Ryerson CJ, Flexman A, Street J, Flexman A, Rivers C, Kuerban D, Cheng C, Noonan V, Dvorak M, Fisher C, Kwon B, Street J, Ailon T, Boyd M, Dvorak M, Fisher C, Kwon B, Paquette S, Street J, Lewis S, Reilly C, Shah SA, Clements DH, Samdani AF, Desai S, Lonner BS, Shufflebarger HL, Betz RR, Newton P, Johnson M, Passmore S, Goytan M, Manson N, Bigney E, Wagg K, Abraham E, Nater A, Tetreault L, Kopjar B, Arnold P, Dekutoski M, Finkelstein J, Fisher C, France J, Gokaslan Z, Massicotte E, Rhines L, Rose P, Sahgal A, Schuster J, Vaccaro A, Leck E, Christie S, Leck E, Christie S, Dakson A, Christie S, Weber M, McIntosh G, Barker J, Golan J, Wagg K, Armstrong M, Bigney E, Daly E, Manson N, Bigney E, Wagg K, Daly E, Abraham E, Perruccio A, Badley E, Rampersaud R. 2016 Canadian Spine Society Abstracts. Can J Surg 2016; 59:S39-63. [PMID: 27240290 DOI: 10.1503/cjs.006916] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
27
|
|
28
|
Rule S, Smith P, Johnson PWM, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S, Kirkwood AA, Kruger A, Pocock C, Seymour JF, Toncheva M, Walewski J, Linch D. The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. Haematologica 2016; 101:235-40. [PMID: 26611473 PMCID: PMC4938327 DOI: 10.3324/haematol.2015.128710] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2015] [Accepted: 11/19/2015] [Indexed: 11/09/2022] Open
Abstract
Mantle cell lymphoma is an incurable and generally aggressive lymphoma that is more common in elderly patients. Whilst a number of different chemotherapeutic regimens are active in this disease, there is no established gold standard therapy. Rituximab has been used widely to good effect in B-cell malignancies but there is no evidence that it improves outcomes when added to chemotherapy in this disease. We performed a randomized, open-label, multicenter study looking at the addition of rituximab to the standard chemotherapy regimen of fludarabine and cyclophosphamide in patients with newly diagnosed mantle cell lymphoma. A total of 370 patients were randomized. With a median follow up of six years, rituximab improved the median progression-free survival from 14.9 to 29.8 months (P<0.001) and overall survival from 37.0 to 44.5 months (P=0.005). This equates to absolute differences of 9.0% and 22.1% for overall and progression-free survival, respectively, at two years. Overall response rates were similar, but complete response rates were significantly higher in the rituximab arm: 52.7% vs. 39.9% (P=0.014). There was no clinically significant additional toxicity observed with the addition of rituximab. Overall, approximately 18% of patients died of non-lymphomatous causes, most commonly infections. The addition of rituximab to fludarabine and cyclophosphamide chemotherapy significantly improves outcomes in patients with mantle cell lymphoma. However, these regimens have significant late toxicity and should be used with caution. This trial has been registered (ISRCTN81133184 and clinicaltrials.gov:00641095) and is supported by the UK National Cancer Research Network.
Collapse
Affiliation(s)
| | - Paul Smith
- Cancer Reasearch UK and UCL Cancer Trials Centre, London, UK
| | | | | | | | - Joanne Gambell
- Cancer Reasearch UK and UCL Cancer Trials Centre, London, UK
| | | | | | | | - Amy A Kirkwood
- Cancer Reasearch UK and UCL Cancer Trials Centre, London, UK
| | | | | | | | - Milena Toncheva
- Cancer Reasearch UK and UCL Cancer Trials Centre, London, UK
| | - Jan Walewski
- Maria Sklodowska-Curie Institute and Oncology Centre, Gilwice, Poland
| | | |
Collapse
|
29
|
Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Al Seraihi AF, Richter J, Bernhart SH, Efeyan A, Iqbal S, Matthews J, Clear A, Guerra-Assunção JA, Bödör C, Quentmeier H, Mansbridge C, Johnson P, Davies A, Strefford JC, Packham G, Barrans S, Jack A, Du MQ, Calaminici M, Lister TA, Auer R, Montoto S, Gribben JG, Siebert R, Chelala C, Zoncu R, Sabatini DM, Fitzgibbon J. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nat Genet 2016; 48:183-8. [PMID: 26691987 PMCID: PMC4731318 DOI: 10.1038/ng.3473] [Citation(s) in RCA: 123] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2015] [Accepted: 11/23/2015] [Indexed: 12/13/2022]
Abstract
Follicular lymphoma is an incurable B cell malignancy characterized by the t(14;18) translocation and mutations affecting the epigenome. Although frequent gene mutations in key signaling pathways, including JAK-STAT, NOTCH and NF-κB, have also been defined, the spectrum of these mutations typically overlaps with that in the closely related diffuse large B cell lymphoma (DLBCL). Using a combination of discovery exome and extended targeted sequencing, we identified recurrent somatic mutations in RRAGC uniquely enriched in patients with follicular lymphoma (17%). More than half of the mutations preferentially co-occurred with mutations in ATP6V1B2 and ATP6AP1, which encode components of the vacuolar H(+)-ATP ATPase (V-ATPase) known to be necessary for amino acid-induced activation of mTORC1. The RagC variants increased raptor binding while rendering mTORC1 signaling resistant to amino acid deprivation. The activating nature of the RRAGC mutations, their existence in the dominant clone and their stability during disease progression support their potential as an excellent candidate for therapeutic targeting.
Collapse
Affiliation(s)
- Jessica Okosun
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - Rachel L Wolfson
- Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Department of Biology, Cambridge, Massachusetts, USA
- Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
| | - Jun Wang
- Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - Shamzah Araf
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - Lucy Wilkins
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - Brian M Castellano
- Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, California, USA
| | - Leire Escudero-Ibarz
- Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, UK
| | - Ahad Fahad Al Seraihi
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - Julia Richter
- Institute of Human Genetics, University Hospital Schleswig-Holstein Campus Kiel and Christian Albrechts University Kiel, Kiel, Germany
| | - Stephan H Bernhart
- Transcriptome Bioinformatics, LIFE Research Center for Civilization Diseases, Leipzig, Germany
- Interdisciplinary Center for Bioinformatics, University of Leipzig, Leipzig, Germany
- Bioinformatics Group, Department of Computer Science, University of Leipzig, Leipzig, Germany
| | - Alejo Efeyan
- Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Department of Biology, Cambridge, Massachusetts, USA
- Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
| | - Sameena Iqbal
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - Janet Matthews
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - Andrew Clear
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | | | - Csaba Bödör
- MTA-SE Lendulet Molecular Oncohematology Research Group, 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
| | - Hilmar Quentmeier
- Leibniz Institute DSMZ, German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany
| | | | - Peter Johnson
- Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, UK
| | - Andrew Davies
- Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, UK
| | - Jonathan C Strefford
- Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, UK
| | - Graham Packham
- Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, UK
| | - Sharon Barrans
- Haematological Malignancy Diagnostic Service, St. James's Institute of Oncology, Leeds, UK
| | - Andrew Jack
- Haematological Malignancy Diagnostic Service, St. James's Institute of Oncology, Leeds, UK
| | - Ming-Qing Du
- Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, UK
| | - Maria Calaminici
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - T Andrew Lister
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - Rebecca Auer
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - Silvia Montoto
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - John G Gribben
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - Reiner Siebert
- Institute of Human Genetics, University Hospital Schleswig-Holstein Campus Kiel and Christian Albrechts University Kiel, Kiel, Germany
| | - Claude Chelala
- Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - Roberto Zoncu
- Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, California, USA
| | - David M Sabatini
- Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Department of Biology, Cambridge, Massachusetts, USA
- Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
- Koch Institute for Integrative Cancer Research, Cambridge, Massachusetts, USA
- Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA
| | - Jude Fitzgibbon
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| |
Collapse
|
30
|
Gleeson M, Hawkes EA, Cunningham D, Jack A, Linch D. Caution in the Use of Immunohistochemistry for Determination of Cell of Origin in Diffuse Large B-Cell Lymphoma. J Clin Oncol 2015; 33:3215-6. [PMID: 26261254 DOI: 10.1200/jco.2014.60.6731] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2024] Open
Affiliation(s)
- Mary Gleeson
- The Royal Marsden Hospital, London and Surrey, United Kingdom
| | - Eliza A Hawkes
- The Royal Marsden Hospital, London and Surrey, United Kingdom
| | | | - Andrew Jack
- St James' Institute of Oncology, Leeds, United Kingdom
| | - David Linch
- University College London, London, United Kingdom
| |
Collapse
|
31
|
Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, André M, Johnson PW, Pfreundschuh M, Ladetto M. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 Suppl 5:v116-25. [PMID: 26314773 DOI: 10.1093/annonc/mdv304] [Citation(s) in RCA: 503] [Impact Index Per Article: 55.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Affiliation(s)
- H Tilly
- Centre Henri-Becquerel, Université de Rouen, Rouen, France
| | | | - U Vitolo
- A.O. Città della Salute e della Scienza di Torino, Turin, Italy
| | - A Jack
- St James's University Hospital, Leeds, UK
| | - M Meignan
- Henri Mondor University Hospital, Créteil, France
| | | | - J Walewski
- Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland
| | - M André
- CHU Dinant-Godinne, UCL Namur, Yvoir, Belgium
| | - P W Johnson
- Cancer Research UK, University of Southampton, Southampton, UK
| | - M Pfreundschuh
- Innere Medizin I, Universität des Saarlandes, Hamburg, Germany
| | - M Ladetto
- Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| |
Collapse
|
32
|
Jackson AE, Mian M, Kalpadakis C, Pangalis GA, Stathis A, Porro E, Conconi A, Cortelazzo S, Gaidano G, Lopez Guillermo A, Johnson PW, Martelli M, Martinelli G, Thieblemont C, McPhail ED, Copie-Bergman C, Pileri SA, Jack A, Campo E, Mazzucchelli L, Ristow K, Habermann TM, Cavalli F, Nowakowski GS, Zucca E. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). Oncologist 2015; 20:1149-53. [PMID: 26268740 DOI: 10.1634/theoncologist.2015-0180] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2015] [Accepted: 06/09/2015] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND The salivary gland is one of the most common sites involved by nongastric, extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT). A large series of patients with long-term follow-up has not been documented. This multicenter, international study sought to characterize the clinical characteristics, treatment, and natural history of salivary gland MALT lymphoma. METHODS Patients with biopsy-confirmed salivary gland MALT lymphoma were identified from multiple international sites. Risk factors, treatment, and long-term outcomes were evaluated. RESULTS A total of 247 patients were evaluated; 76% presented with limited-stage disease. There was a history of autoimmune disorder in 41%, with Sjögren disease being the most common (83%). Fifty-seven percent of patients were initially treated with local therapy with surgery, radiation, or both; 37 of patients were treated with systemic therapy initially, with 47% of those receiving rituximab; and 6% of patients were observed. The median overall survival (OS) was 18.3 years. The median progression-free survival (PFS) following primary therapy was 9.3 years. There was no difference in the outcomes between patients receiving local or systemic therapy in first-line management. On multivariate analysis, age <60 years and low to intermediate international prognostic index were associated with improved OS and PFS; Sjögren disease was associated with improved OS. CONCLUSION Salivary gland MALT lymphoma has an excellent prognosis regardless of initial treatment, and patients with Sjögren disease have improved survival. Risks for long-term complications must be weighed when determining initial therapy.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Chemotherapy, Adjuvant
- Disease-Free Survival
- Female
- Humans
- Lymphoma, B-Cell, Marginal Zone/complications
- Lymphoma, B-Cell, Marginal Zone/mortality
- Lymphoma, B-Cell, Marginal Zone/pathology
- Lymphoma, B-Cell, Marginal Zone/therapy
- Male
- Middle Aged
- Prognosis
- Rituximab/therapeutic use
- Salivary Gland Neoplasms/mortality
- Salivary Gland Neoplasms/pathology
- Salivary Gland Neoplasms/therapy
- Sjogren's Syndrome/complications
- Treatment Outcome
- Young Adult
Collapse
Affiliation(s)
- Amie E Jackson
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Michael Mian
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Christina Kalpadakis
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Gerassimos A Pangalis
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Anastasios Stathis
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Elena Porro
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Annarita Conconi
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Sergio Cortelazzo
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Gianluca Gaidano
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | | | - Peter W Johnson
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Maurizio Martelli
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Giovanni Martinelli
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Catherine Thieblemont
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Ellen D McPhail
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Christiane Copie-Bergman
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Stefano A Pileri
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Andrew Jack
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Elias Campo
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Luca Mazzucchelli
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Kay Ristow
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Thomas M Habermann
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Franco Cavalli
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Grzegorz S Nowakowski
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| | - Emanuele Zucca
- Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland
| |
Collapse
|
33
|
Wang M, Escudero-Ibarz L, Moody S, Zeng N, Clipson A, Huang Y, Xue X, Grigoropoulos NF, Barrans S, Worrillow L, Forshew T, Su J, Firth A, Martin H, Jack A, Brugger K, Du MQ. Somatic Mutation Screening Using Archival Formalin-Fixed, Paraffin-Embedded Tissues by Fluidigm Multiplex PCR and Illumina Sequencing. J Mol Diagn 2015; 17:521-32. [PMID: 26165823 DOI: 10.1016/j.jmoldx.2015.04.008] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2015] [Revised: 04/02/2015] [Accepted: 04/27/2015] [Indexed: 01/03/2023] Open
Abstract
High-throughput somatic mutation screening using FFPE tissues is a major challenge because of a lack of established methods and validated variant calling algorithms. We aimed to develop a targeted sequencing protocol by Fluidigm multiplex PCR and Illumina sequencing and to establish a companion variant calling algorithm. The experimental protocol and variant calling algorithm were first developed and optimized against a series of somatic mutations (147 substitutions, 12 indels ranging from 1 to 33 bp) in seven genes, previously detected by Sanger sequencing of DNA from 163 FFPE lymphoma biopsy specimens. The optimized experimental protocol and variant calling algorithm were further ascertained in two separate experiments by including the seven genes as a part of larger gene panels (22 or 13 genes) using FFPE and high-molecular-weight lymphoma DNAs, respectively. We found that most false-positive variants were due to DNA degradation, deamination, and Taq polymerase errors, but they were nonreproducible and could be efficiently eliminated by duplicate experiments. A small fraction of false-positive variants appeared in duplicate, but they were at low alternative allele frequencies and could be separated from mutations when appropriate threshold value was used. In conclusion, we established a robust practical approach for high-throughput mutation screening using archival FFPE tissues.
Collapse
Affiliation(s)
- Ming Wang
- Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
| | - Leire Escudero-Ibarz
- Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
| | - Sarah Moody
- Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
| | - Naiyan Zeng
- Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
| | - Alexandra Clipson
- Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
| | - Yuanxue Huang
- Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
| | - Xuemin Xue
- Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
| | - Nicholas F Grigoropoulos
- Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
| | - Sharon Barrans
- Haematological Malignancy Diagnostic Service, St. James's Institute of Oncology, Leeds, United Kingdom
| | - Lisa Worrillow
- Haematological Malignancy Diagnostic Service, St. James's Institute of Oncology, Leeds, United Kingdom
| | - Tim Forshew
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom
| | - Jing Su
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom
| | - Andrew Firth
- Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
| | - Howard Martin
- Department of Molecular Genetics, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
| | - Andrew Jack
- Haematological Malignancy Diagnostic Service, St. James's Institute of Oncology, Leeds, United Kingdom
| | - Kim Brugger
- Department of Molecular Genetics, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
| | - Ming-Qing Du
- Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
| |
Collapse
|
34
|
Sha C, Barrans S, Care MA, Cunningham D, Tooze RM, Jack A, Westhead DR. Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas. Genome Med 2015; 7:64. [PMID: 26207141 PMCID: PMC4512160 DOI: 10.1186/s13073-015-0187-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2015] [Accepted: 06/15/2015] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Classifiers based on molecular criteria such as gene expression signatures have been developed to distinguish Burkitt lymphoma and diffuse large B cell lymphoma, which help to explore the intermediate cases where traditional diagnosis is difficult. Transfer of these research classifiers into a clinical setting is challenging because there are competing classifiers in the literature based on different methodology and gene sets with no clear best choice; classifiers based on one expression measurement platform may not transfer effectively to another; and, classifiers developed using fresh frozen samples may not work effectively with the commonly used and more convenient formalin fixed paraffin-embedded samples used in routine diagnosis. METHODS Here we thoroughly compared two published high profile classifiers developed on data from different Affymetrix array platforms and fresh-frozen tissue, examining their transferability and concordance. Based on this analysis, a new Burkitt and diffuse large B cell lymphoma classifier (BDC) was developed and employed on Illumina DASL data from our own paraffin-embedded samples, allowing comparison with the diagnosis made in a central haematopathology laboratory and evaluation of clinical relevance. RESULTS We show that both previous classifiers can be recapitulated using very much smaller gene sets than originally employed, and that the classification result is closely dependent on the Burkitt lymphoma criteria applied in the training set. The BDC classification on our data exhibits high agreement (~95 %) with the original diagnosis. A simple outcome comparison in the patients presenting intermediate features on conventional criteria suggests that the cases classified as Burkitt lymphoma by BDC have worse response to standard diffuse large B cell lymphoma treatment than those classified as diffuse large B cell lymphoma. CONCLUSIONS In this study, we comprehensively investigate two previous Burkitt lymphoma molecular classifiers, and implement a new gene expression classifier, BDC, that works effectively on paraffin-embedded samples and provides useful information for treatment decisions. The classifier is available as a free software package under the GNU public licence within the R statistical software environment through the link http://www.bioinformatics.leeds.ac.uk/labpages/softwares/ or on github https://github.com/Sharlene/BDC.
Collapse
Affiliation(s)
- Chulin Sha
- />School of Molecular and Cellular Biology, Garstang Building, University of Leeds, Leeds, LS2 9JT UK
| | - Sharon Barrans
- />Haematological, Malignancy Diagnostic Service, St James’s University Hospital, Leeds, UK
| | - Matthew A. Care
- />Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
| | | | - Reuben M. Tooze
- />Haematological, Malignancy Diagnostic Service, St James’s University Hospital, Leeds, UK
- />Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
| | - Andrew Jack
- />Haematological, Malignancy Diagnostic Service, St James’s University Hospital, Leeds, UK
| | - David R. Westhead
- />School of Molecular and Cellular Biology, Garstang Building, University of Leeds, Leeds, LS2 9JT UK
| |
Collapse
|
35
|
|
36
|
|
37
|
Bailey C, Stratton A, Manson N, Layne E, McKeon M, Harris S, McIntosh G, DellaMora L, McIntosh G, Miyanji F, Joukhadar N, Miyanji F, Miyanji F, Miyanji F, Miyanji F, Larouche J, Aoude A, Hardy-St-Pierre G, Roffey D, Evaniew N, Fazli G, Lin C, Dea N, Flood M, Glennie RA, Millstone DB, Nater A, Witiw C, Maggio D, Harris S, Collings D, Yee A, Tetreault L, Street J, Phillips J, Cochran M, Bigney E, Bouchard J, Jack A, Shamji M, Shamji M, Nakashima H, Chaudhary BR, Johnson M, Manson N, Tetreault L, Glennie RA, Evaniew N, Morris S, Spurway A, Bateman A, Abduljabbar F, Shamji M, McLachlin S, Manson N, Palkovsky R, Ailon T, Tetreault L, Johnson M, Street J, Street J, Bourassa-Moreau E, Nouri A, McIntosh G, Contreras A, Phan P, Hardy-St-Pierre G, Jarzem P, Wu H, Parsons D, Chukwunyerenwa C, Nadeau M, Bailey S, Rosas-Arellano P, Dehens S, Sequeira K, Miller T, Watson J, Siddiqi F, Gurr K, Urquhart J, Thomas K, McIntosh G, Hirsch L, Abraham E, Green A, McIntosh G, Roffey D, Wilson C, Kingwell S, Wai E, Manson N, Abraham E, Taylor E, Murray J, Albert W, Rampersaud R, Hall H, Carter T, Gregg C, Perruccio AV, Badley EM, Rampersaud YR, Steenstra I, Hall H, Carter T, Bastrom T, Samdani A, Yaszay B, Clements D, Shah S, Marks M, Betz R, Shufflebarger H, Newton P, Skaggs D, Heflin J, Yasin M, El-Hawary R, Bastrom T, Samdani A, Yaszay B, Asghar J, Shah S, Betz R, Shufflebarger H, Newton P, Reilly C, Choi J, Mok J, Nitikman M, Desai S, Reilly C, Desai S, Doddabasappa S, Reilly C, Nitikman M, Desai S, Paquette S, Fisher C, Domisse I, Wadey V, Hall H, Finkelstein J, Bouchard J, Hurlbert J, Broad R, Fox R, Hedden D, Nataraj A, Carey T, Bailey C, Chapman M, Moroz P, Chow D, Wai E, Tsai E, Christie S, Lundine K, Paquet J, Splawinski J, Wheelock B, Goytan M, Ahn H, Massicotte E, Fehlings M, Yee A, Alhamzah H, Fortin M, Jarzem P, Ouellet J, Weber M, Jack A, Thomas KC, Nataraj A, Coyle M, Kingwell S, Wai E, van der Watt L, Bhandari M, Ghert M, Aleem I, Drew B, Guyatt G, Jeyaratnam J, Nandlall N, Coyte P, Rampersaud R, Witiw C, Sundararajan K, Rampersaud YR, Fisher C, Batke J, Street J, Abraham E, Green A, Manson N, Ailon T, Batke J, Dea N, Street J, Perruccio AV, Badley EM, Rampersaud YR, Fehlings M, Tetreault L, Kopjar B, Fisher C, Vaccaro A, Arnold P, Schuster J, Finkelstein J, Rhines L, Dekutoski M, Gokaslan Z, France J, Rose P, Lin C, Sundararajan K, Rampersaud YR, Ailon T, Smith J, Shaffrey C, Lafage V, Schwab F, Haid R, Protopsaltis T, Klineberg E, Scheer J, Bess S, Arnold P, Chapman J, Fehlings M, Ames C, Rampersaud R, Nutt L, Urquhart J, Kuska L, Siddiqi F, Gurr K, Bailey C, Burch S, Sahgal A, Chow E, Niu C, Fisher C, Whyne C, Akens M, Bisland S, Wilson B, Nouri A, Cote P, Fehlings M, Mendelsohn D, Strelzow J, Batke J, Dvorak M, Fisher C, Urquhart J, Tallon C, Gurr K, Siddiqi F, Bailey S, Bailey C, Abraham E, Green A, Manson N, Manson NA, Green AJ, Abraham EP, Hurlbert J, Mogadham K, Swamy G, Tsahtsarlis A, Siddiqui M, Pierre GHS, Nataraj A, Mohanty C, Massicotte E, Fehlings M, Shcharinsky A, Tetreault L, Nagoshi N, Aria N, Fehlings M, Amritanand R, Rampersaud YR, Passmore S, McIntosh G, Abraham E, Green A, McIntosh G, Kopjar B, Cote P, Fehlings M, Arnold P, Batke J, Dea N, Dvorak M, Noonan V, Street J, Khan M, Drew B, Kwok D, Bhandari M, Ghert M, Howard J, Rasmusson D, El-Hawary R, Kishta W, Chukwunyerenwa C, El-Hawary R, Balkovec C, Akens M, Harrison R, McGill S, Yee A, Al-Jurayyan A, Alqahtani S, Sardar Z, Saluja RS, Ouellet J, Weber M, Steffen T, Beckman L, Jarzem P, Tu Y, Salter M, Polley B, Beig M, Larouche J, Whyne C, Green A, McIntosh G, Abraham E, Nicholls F, Burch S, Wagner P, Zhou H, Egge N, Harrigan M, Lapinsky A, Connoly P, Street J, DiPaola C, Kopjar B, Tan G, Cote P, Fehlings M, Passmore S, Street J, Fisher C, McIntosh G, Perlus IR, Kennedy J, Lenehan B, Strelzow J, Mendelsohn D, Dea N, Dvorak M, Fisher C, Mac-Thiong JM, Parent S, Li A, Thompson C, Tetreault L, Zamorano J, Dalzell K, Davis A, Mikulis D, Yee A, Fehlings M, Hall H, Carter T, Gregg C, Batke J, Dea N, Dvorak MF, Fisher CG, Street J, Le V(B, Roffey D, Kingwell S, MacPherson P, Desjardins M, Wai E, Siddiqui M, Henderson RL, Nataraj A, Simoes L, Assaker R, Ritter-Lang K, Vardon D, Litrico S, Fuentes S, Putzier M, Frank J, Guigui P, Nakach G, Le Huec JC, Pennington A, Batke J, Yang K, Fisher CG, Dvorak MF, Street J, Da Cunha R, Al Sayegh S, LaMothe J, Letal M, Johal H, Ferri-de-Barros F, El-Hawary R, Gauthier L, Spurway A, Johnston C, McClung A, Batke J, Lauscher HN, Fischer C, Street J. Canadian spine society 15th annual scientific conference. Can J Surg 2015; 58:S43-70. [PMID: 26011856 DOI: 10.1503/cjs.005515] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
38
|
Painter D, Smith A, de Tute R, Crouch S, Roman E, Jack A. The clinical impact of staging bone marrow examination on treatment decisions and prognostic assessment of lymphoma patients. Br J Haematol 2015; 170:175-8. [DOI: 10.1111/bjh.13412] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2014] [Accepted: 02/16/2015] [Indexed: 11/28/2022]
Affiliation(s)
- Dan Painter
- Epidemiology and Cancer Statistics Group; University of York; York UK
| | - Alexandra Smith
- Epidemiology and Cancer Statistics Group; University of York; York UK
| | - Ruth de Tute
- Haematological Malignancy Diagnostic Service; Leeds Cancer Centre Leeds; Leeds UK
| | - Simon Crouch
- Epidemiology and Cancer Statistics Group; University of York; York UK
| | - Eve Roman
- Epidemiology and Cancer Statistics Group; University of York; York UK
| | - Andrew Jack
- Haematological Malignancy Diagnostic Service; Leeds Cancer Centre Leeds; Leeds UK
| |
Collapse
|
39
|
Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K, Leung W, Godfrey AL, Guglielmelli P, Callaway A, Ward D, Aranaz P, White HE, Waghorn K, Lin F, Chase A, Joanna Baxter E, Maclean C, Nangalia J, Chen E, Evans P, Short M, Jack A, Wallis L, Oscier D, Duncombe AS, Schuh A, Mead AJ, Griffiths M, Ewing J, Gale RE, Schnittger S, Haferlach T, Stegelmann F, Döhner K, Grallert H, Strauch K, Tanaka T, Bandinelli S, Giannopoulos A, Pieri L, Mannarelli C, Gisslinger H, Barosi G, Cazzola M, Reiter A, Harrison C, Campbell P, Green AR, Vannucchi A, Cross NC. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nat Commun 2015; 6:6691. [PMID: 25849990 PMCID: PMC4396373 DOI: 10.1038/ncomms7691] [Citation(s) in RCA: 135] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2014] [Accepted: 02/20/2015] [Indexed: 12/21/2022] Open
Abstract
Clonal proliferation in myeloproliferative neoplasms (MPN) is driven by somatic mutations in JAK2, CALR or MPL, but the contribution of inherited factors is poorly characterized. Using a three-stage genome-wide association study of 3,437 MPN cases and 10,083 controls, we identify two SNPs with genome-wide significance in JAK2(V617F)-negative MPN: rs12339666 (JAK2; meta-analysis P=1.27 × 10(-10)) and rs2201862 (MECOM; meta-analysis P=1.96 × 10(-9)). Two additional SNPs, rs2736100 (TERT) and rs9376092 (HBS1L/MYB), achieve genome-wide significance when including JAK2(V617F)-positive cases. rs9376092 has a stronger effect in JAK2(V617F)-negative cases with CALR and/or MPL mutations (Breslow-Day P=4.5 × 10(-7)), whereas in JAK2(V617F)-positive cases rs9376092 associates with essential thrombocythemia (ET) rather than polycythemia vera (allelic χ(2) P=7.3 × 10(-7)). Reduced MYB expression, previously linked to development of an ET-like disease in model systems, associates with rs9376092 in normal myeloid cells. These findings demonstrate that multiple germline variants predispose to MPN and link constitutional differences in MYB expression to disease phenotype.
Collapse
Affiliation(s)
- William Tapper
- Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK
- Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury SP2 8BJ, UK
| | - Amy V. Jones
- Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK
- Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury SP2 8BJ, UK
| | - Robert Kralovics
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna 1090, Austria
| | - Ashot S. Harutyunyan
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna 1090, Austria
| | - Katerina Zoi
- Haematology Research Laboratory, Biomedical Research Foundation, Academy of Athens, Athens 11527, Greece
| | - William Leung
- Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK
- Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury SP2 8BJ, UK
| | - Anna L. Godfrey
- Department of Haematology, Addenbrooke’s Hospital, Cambridge CB2 0XY, UK
- Department of Haematology, University of Cambridge, Cambridge CB2 0XY, UK
| | - Paola Guglielmelli
- Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence 50134, Italy
| | - Alison Callaway
- Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury SP2 8BJ, UK
| | - Daniel Ward
- Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury SP2 8BJ, UK
| | - Paula Aranaz
- Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury SP2 8BJ, UK
| | - Helen E. White
- Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK
- Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury SP2 8BJ, UK
| | - Katherine Waghorn
- Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK
- Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury SP2 8BJ, UK
| | - Feng Lin
- Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK
- Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury SP2 8BJ, UK
| | - Andrew Chase
- Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK
- Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury SP2 8BJ, UK
| | - E. Joanna Baxter
- Department of Haematology, Addenbrooke’s Hospital, Cambridge CB2 0XY, UK
- Department of Haematology, University of Cambridge, Cambridge CB2 0XY, UK
| | - Cathy Maclean
- Department of Haematology, Addenbrooke’s Hospital, Cambridge CB2 0XY, UK
- Department of Haematology, University of Cambridge, Cambridge CB2 0XY, UK
| | - Jyoti Nangalia
- Department of Haematology, Addenbrooke’s Hospital, Cambridge CB2 0XY, UK
- Department of Haematology, University of Cambridge, Cambridge CB2 0XY, UK
| | - Edwin Chen
- Department of Haematology, Addenbrooke’s Hospital, Cambridge CB2 0XY, UK
- Department of Haematology, University of Cambridge, Cambridge CB2 0XY, UK
| | - Paul Evans
- Haematological Malignancy Diagnostic Service, St James's Institute of Oncology, Bexley Wing, St James's University Hospital, Leeds LS9 7TF, UK
| | - Michael Short
- Haematological Malignancy Diagnostic Service, St James's Institute of Oncology, Bexley Wing, St James's University Hospital, Leeds LS9 7TF, UK
| | - Andrew Jack
- Haematological Malignancy Diagnostic Service, St James's Institute of Oncology, Bexley Wing, St James's University Hospital, Leeds LS9 7TF, UK
| | - Louise Wallis
- Department of Haematology, Royal Bournemouth Hospital, Bournemouth BH7 7DW, UK
| | - David Oscier
- Department of Haematology, Royal Bournemouth Hospital, Bournemouth BH7 7DW, UK
| | - Andrew S. Duncombe
- Department of Haematology, University Hospital Southampton, Southampton SO16 6YD, UK
| | - Anna Schuh
- Oxford Biomedical Research Centre, Molecular Diagnostic Laboratory, Oxford University Hospitals NHS Trust, Oxford OX3 7LE, UK
| | - Adam J. Mead
- Haematopoietic Stem Cell Biology Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK
| | - Michael Griffiths
- School of Cancer Sciences, University of Birmingham,, Birmingham B15 2TT, UK
- West Midlands Regional Genetics Laboratory, Birmingham Women's NHS Foundation Trust, Birmingham B15 2TG, UK
| | - Joanne Ewing
- Birmingham Heartlands Hospital, Birmingham B9 5SS, UK
| | - Rosemary E. Gale
- Department of Haematology, UCL Cancer Institute, London WC1 E6BT, UK
| | | | | | - Frank Stegelmann
- Department of Internal Medicine III, University Hospital of Ulm, Ulm 89081, Germany
| | - Konstanze Döhner
- Department of Internal Medicine III, University Hospital of Ulm, Ulm 89081, Germany
| | - Harald Grallert
- Institute of Epidemiology II, Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg 85764, Germany
- German Center for Diabetes Research, Neuherberg 85764, Germany
| | - Konstantin Strauch
- Institute of Epidemiology II, Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg 85764, Germany
- Institute of Medical Informatics, Biometry and Epidemiology, Chair of Genetic Epidemiology, Ludwig-Maximilians-Universität, 80539 Munich, Germany
| | - Toshiko Tanaka
- Longitudinal Study Section, Translational Gerontology Branch, National Institute on Aging, Baltimore, Maryland 21224-6825, USA
| | | | - Andreas Giannopoulos
- Haematology Research Laboratory, Biomedical Research Foundation, Academy of Athens, Athens 11527, Greece
| | - Lisa Pieri
- Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence 50134, Italy
| | - Carmela Mannarelli
- Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence 50134, Italy
| | - Heinz Gisslinger
- Medical University of Vienna, Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Vienna 1090, Austria
| | - Giovanni Barosi
- Center for the Study of Myelofibrosis, IRCCS Policlinico San Matteo Foundation, Pavia 27100, Italy
| | - Mario Cazzola
- Department of Molecular Medicine, University of Pavia, Pavia, Italy
- Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia 27100, Italy
| | - Andreas Reiter
- III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim 68167, Germany
| | - Claire Harrison
- Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 9RT, UK
| | - Peter Campbell
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
| | - Anthony R. Green
- Department of Haematology, Addenbrooke’s Hospital, Cambridge CB2 0XY, UK
- Department of Haematology, University of Cambridge, Cambridge CB2 0XY, UK
| | - Alessandro Vannucchi
- Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence 50134, Italy
| | - Nicholas C.P. Cross
- Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK
- Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury SP2 8BJ, UK
| |
Collapse
|
40
|
Cargo C, Evans P, Taylor J, Crouch S, Jack A. 145 MDS ASSOCIATED DRIVER MUTATIONS ARE FREQUENT IN CYTOPENIC PATIENTS. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30146-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
41
|
Clipson A, Barrans S, Zeng N, Crouch S, Grigoropoulos NF, Liu H, Kocialkowski S, Wang M, Huang Y, Worrillow L, Goodlad J, Buxton J, Neat M, Fields P, Wilkins B, Grant JW, Wright P, Ei-Daly H, Follows GA, Roman E, Watkins AJ, Johnson PWM, Jack A, Du MQ. The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit. J Pathol Clin Res 2015; 1:125-133. [PMID: 27347428 PMCID: PMC4915334 DOI: 10.1002/cjp2.10] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/01/2014] [Accepted: 12/23/2014] [Indexed: 12/14/2022]
Abstract
A proportion of MYC translocation positive diffuse large B‐cell lymphomas (DLBCL) harbour a BCL2 and/or BCL6 translocation, known as double‐hit DLBCL, and are clinically aggressive. It is unknown whether there are other genetic abnormalities that cooperate with MYC translocation and form double‐hit DLBCL, and whether there is a difference in clinical outcome between the double‐hit DLBCL and those with an isolated MYC translocation. We investigated TP53 gene mutations along with BCL2 and BCL6 translocations in a total of 234 cases of DLBCL, including 81 with MYC translocation. TP53 mutations were investigated by PCR and sequencing, while BCL2 and BCL6 translocation was studied by interphase fluorescence in situ hybridization. The majority of MYC translocation positive DLBCLs (60/81 = 74%) had at least one additional genetic hit. In MYC translocation positive DLBCL treated by R‐CHOP (n = 67), TP53 mutation and BCL2, but not BCL6 translocation had an adverse effect on patient overall survival. In comparison with DLBCL with an isolated MYC translocation, cases with MYC/TP53 double‐hits had the worst overall survival, followed by those with MYC/BCL2 double‐hits. In MYC translocation negative DLBCL treated by R‐CHOP (n = 101), TP53 mutation, BCL2 and BCL6 translocation had no impact on patient survival. The prognosis of MYC translocation positive DLBCL critically depends on the second hit, with TP53 mutations and BCL2 translocation contributing to an adverse prognosis. It is pivotal to investigate both TP53 mutations and BCL2 translocations in MYC translocation positive DLBCL, and to distinguish double‐hit DLBCLs from those with an isolated MYC translocation.
Collapse
Affiliation(s)
- Alexandra Clipson
- Division of Molecular Histopathology Department of Pathology University of Cambridge UK
| | - Sharon Barrans
- Haematological Malignancy Diagnostic Service St. James's Institute of Oncology Leeds UK
| | - Naiyan Zeng
- Division of Molecular Histopathology Department of Pathology University of Cambridge UK
| | - Simon Crouch
- Department of Health Sciences Epidemiology and Cancer Statistics Group University of York York UK
| | - Nicholas F Grigoropoulos
- Division of Molecular HistopathologyDepartment of PathologyUniversity of CambridgeUK; Department of HaematologyAddenbrooke's Hospital, Cambridge University Hospitals NHS Foundation TrustCambridgeUK
| | - Hongxiang Liu
- Department of Histopathology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust Cambridge UK
| | - Sylvia Kocialkowski
- Division of Molecular Histopathology Department of Pathology University of Cambridge UK
| | - Ming Wang
- Division of Molecular Histopathology Department of Pathology University of Cambridge UK
| | - Yuanxue Huang
- Division of Molecular Histopathology Department of Pathology University of Cambridge UK
| | - Lisa Worrillow
- Haematological Malignancy Diagnostic Service St. James's Institute of Oncology Leeds UK
| | - John Goodlad
- Department of Pathology Western General Hospital Edinburgh UK
| | - Jenny Buxton
- Department of Haematology Western General Hospital Edinburgh UK
| | - Michael Neat
- Department of Haematology and Department of Cytogenetics GSTS Pathology Guy's and St. Thomas NHS Foundation Trust London UK
| | - Paul Fields
- Department of Haematology GSST Kings Health Partners London UK
| | - Bridget Wilkins
- Histopathology Department St Thomas' Hospital and King's College London UK
| | - John W Grant
- Department of Histopathology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust Cambridge UK
| | - Penny Wright
- Department of Histopathology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust Cambridge UK
| | - Hesham Ei-Daly
- Department of Haematology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust Cambridge UK
| | - George A Follows
- Department of Haematology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust Cambridge UK
| | - Eve Roman
- Department of Health Sciences Epidemiology and Cancer Statistics Group University of York York UK
| | - A James Watkins
- Department of Haematology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust Cambridge UK
| | - Peter W M Johnson
- Cancer Research UK Centre University of Southampton Southampton United Kingdom
| | - Andrew Jack
- Haematological Malignancy Diagnostic Service St. James's Institute of Oncology Leeds UK
| | - Ming-Qing Du
- Division of Molecular HistopathologyDepartment of PathologyUniversity of CambridgeUK; Department of HistopathologyAddenbrooke's Hospital, Cambridge University Hospitals NHS Foundation TrustCambridgeUK
| |
Collapse
|
42
|
Jack A. Will Tamiflu recommendations change this winter? BMJ 2014; 349:g6742. [PMID: 25430733 DOI: 10.1136/bmj.g6742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
43
|
Wang HI, Smith A, Roman E, Crouch S, Jack A, Patmore R. Costed Treatment Pathways of Diffuse Large B Cell Lymphoma in a UK Population-Based Cohort: A Patient Level Simulation Model. Value Health 2014; 17:A624-A625. [PMID: 27202204 DOI: 10.1016/j.jval.2014.08.2221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
| | - A Smith
- University of York, York, UK
| | - E Roman
- University of York, York, UK
| | | | - A Jack
- St James's University Hospital, Leeds, UK
| | | |
Collapse
|
44
|
|
45
|
|
46
|
Farzin B, Brosseau L, Jamali S, Salazkin I, Jack A, Darsaut TE, Raymond J. Flow diverters: inter and intra-rater reliability of porosity and pore density measurements. J Neurointerv Surg 2014; 7:734-9. [DOI: 10.1136/neurintsurg-2014-011240] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2014] [Accepted: 07/11/2014] [Indexed: 11/04/2022]
|
47
|
Care MA, Cocco M, Laye JP, Barnes N, Huang Y, Wang M, Barrans S, Du M, Jack A, Westhead DR, Doody GM, Tooze RM. SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity. Nucleic Acids Res 2014; 42:7591-610. [PMID: 24875472 PMCID: PMC4081075 DOI: 10.1093/nar/gku451] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2013] [Revised: 05/06/2014] [Accepted: 05/08/2014] [Indexed: 01/31/2023] Open
Abstract
Interferon regulatory factor 4 (IRF4) is central to the transcriptional network of activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL), an aggressive lymphoma subgroup defined by gene expression profiling. Since cofactor association modifies transcriptional regulatory input by IRF4, we assessed genome occupancy by IRF4 and endogenous cofactors in ABC-DLBCL cell lines. IRF4 partners with SPIB, PU.1 and BATF genome-wide, but SPIB provides the dominant IRF4 partner in this context. Upon SPIB knockdown IRF4 occupancy is depleted and neither PU.1 nor BATF acutely compensates. Integration with ENCODE data from lymphoblastoid cell line GM12878, demonstrates that IRF4 adopts either SPIB- or BATF-centric genome-wide distributions in related states of post-germinal centre B-cell transformation. In primary DLBCL high-SPIB and low-BATF or the reciprocal low-SPIB and high-BATF mRNA expression links to differential gene expression profiles across nine data sets, identifying distinct associations with SPIB occupancy, signatures of B-cell differentiation stage and potential pathogenetic mechanisms. In a population-based patient cohort, SPIBhigh/BATFlow-ABC-DLBCL is enriched for mutation of MYD88, and SPIBhigh/BATFlow-ABC-DLBCL with MYD88-L265P mutation identifies a small subgroup of patients among this otherwise aggressive disease subgroup with distinct favourable outcome. We conclude that differential expression of IRF4 cofactors SPIB and BATF identifies biologically and clinically significant heterogeneity among ABC-DLBCL.
Collapse
Affiliation(s)
- Matthew A Care
- Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK Bioinformatics Group, School of Molecular and Cellular Biology, University of Leeds, Leeds, UK
| | - Mario Cocco
- Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
| | - Jon P Laye
- Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
| | - Nicholas Barnes
- Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
| | - Yuanxue Huang
- Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, UK
| | - Ming Wang
- Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, UK
| | - Sharon Barrans
- Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Ming Du
- Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, UK
| | - Andrew Jack
- Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - David R Westhead
- Bioinformatics Group, School of Molecular and Cellular Biology, University of Leeds, Leeds, UK
| | - Gina M Doody
- Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
| | - Reuben M Tooze
- Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| |
Collapse
|
48
|
van West H, Hodgson B, Parent E, Samuel S, Hodgson B, Ferland C, Soroceanu A, Soroceanu A, Protopsaltis T, Protopsaltis T, Radovanovic I, Amritanand R, Shamji M, Haugo K, Malham G, Jarzem P, Rampersaud Y, Tomkins-Lane C, Manson N, Malham G, Rampersaud Y, Malham G, Malham G, King V, Goldstein C, Fisher C, Fehlings M, Fisher C, Wong E, Sardar Z, Christie S, Patel A, Pinkoski C, Ahn H, Drew B, Dvorak M, Pezeshki P, Altaf F, Wilde P, Rampersaud Y, Sparrey C, Tetreault L, Fehlings M, Tetreault L, Rampersaud R, Jack A, Johnstone R, Fernandes A, Urquhart J, Morokoff A, Manson N, Tomkins-Lane C, Phan P, Evaniew N, Shamji M, Manson J, Rampersaud Y, Nault ML, St-Pierre GH, Larouche J, Lewis S, Wilgenbusch C, Lewis S, Rampersaud Y, Johnson R, Cushnie D, Sridharan S, Street J, Gregg C, Missiuna P, Abraham E, Abraham E, Manson N, Huang E, Passmore S, Mac-Thiong JM, Labelle H, Moulin D, Turgeon I, Roy-Beaudry M, Bourassa N, Petit Y, Parent. S, Chabot S, Westover L, Hill D, Moreau M, Hedden D, Lou E, Adeeb. S, Smith M, Bridge C, Hsu B, Gray. R, Group PORSCHES, Saran N, Mac-Thiong JM, Stone L, Ouellet. J, Protopsaltis T, Terran J, Bronsard N, Smith J, Klineberg E, Mundis G, Hostin R, Hart R, Shaffrey C, Bess S, Ames C, Schwab F, Lafage. V, Schwab F, Lafage V, Protopsaltis T, Ames C, Bess S, Smith J, Errico. T, Schwab F, Soroceanu A, Bronsard N, Smith J, Klineberg E, Mundis G, Hostin R, Hart R, Burton D, Ames C, Shaffrey C, Bess S, Errico T, Lafage. V, Terran J, Soroceanu A, Bronsard N, Smith J, Klineberg E, Mundis G, Kim HJ, Hostin R, Hart R, Shaffrey C, Bess S, Ames C, Schwab F, Lafage. V, Urquhart J, Gananapathy V, Siddiqi F, Gurr K, Bailey C, Ravi B, David K, Rampersaud. R, Tu Y, Salter. M, Nichol H, Fourney D, Kelly. M, Parker R, Ellis N, Blecher C, Chow F, Claydon. M, Sardar Z, Alexander D, Oxner W, Plessis SD, Yee A, Wai. E, Lewis S, Davey J, Gandhi R, Mahomed. N, Hu R, Thomas K, Hepler C, Choi K, Rowed K, Haig. A, Lam. K, Parker R, Blecher C, Seex. K, Perruccio A, Gandhi R, Program. UHNA, Ellis N, Parker R, Goss B, Blecher C, Ballok. Z, Parker R, Ellis N, Chan P, Varma. D, Swart A, Winder M, Varga PP, Gokaslan Z, Boriani S, Luzzati A, Rhines L, Fisher C, Chou D, Williams R, Dekutoski M, Quraishi N, Bettegowda C, Kawahara N, Fehlings. M, Versteeg A, Boriani S, Varga PP, Dekutoski M, Luzzati A, Gokaslan Z, Williams R, Reynolds J, Fehlings M, Bettegowda C, Rhines. L, Zamorano J, Nater A, Tetrault L, Varga P, Gokaslan Z, Boriani S, Fisher C, Rhines L, Bettegowda C, Kawahara N, Chou. D, Fehlings M, Kopjar B, Vaccaro A, Arnold P, Schuster J, Finkelstein J, Rhines L, Dekutoski M, Gokaslan Z, France. J, Whyne C, Singh D, Ford. M, Aldebeyan W, Ouellet J, Steffen T, Beckman L, Weber M, Jarzem. P, Kwon B, Ahn H, Bailey C, Fehlings M, Fourney D, Gagnon D, Tsai E, Tsui D, Parent S, Chen J, Dvorak M, Noonan V, Rivers C, Network RHSCIR, Batke J, Lenehan B, Fisher C, Dvorak M, Street. J, Fox R, Nataraj A, Bailey C, Christie S, Duggal N, Fehlings M, Finkelstein J, Fourney D, Hurlbert R, Kwon B, Townson A, Tsai E, Attabib N, Chen J, Dvorak M, Noonan V, Rivers C, Network. RHSCIR, Fehlings M, Paquet J, Ahn H, Attabib N, Bailey C, Christie S, Duggal N, Finkelstein J, Fourney D, Hurlbert R, Johnson M, Kwon B, Parent S, Tsai E, Dvorak M, Noonan V, Rivers C, Shen T, Network. RHSCIR, Fisher C, Kwon B, Drew B, Fehlings M, Paquet J, Ahn H, Attabib N, Bailey C, Christie S, Duggal N, Finkelstein J, Fourney D, Hurlbert R, Johnson M, Mac-Thiong JM, Parent S, Tsai E, Fallah N, Noonan V, Rivers C, Network RHSCIR, Davidson S, McCann C, Akens M, Murphy K, Whyne C, Sherar M, Yee. A, Belanger L, Ronco J, Dea N, Paquette S, Boyd M, Street J, Fisher C, Dvorak M, Kwon B, Gonzalvo A, Fitt G, Liew S, de la Harpe D, Turner P, Rogers M, Bidos A, Fanti C, Young B, Drew B, Puskas. D, Tam H, Manansala S, Nosov V, Delva M, Alshafai N, Kopjar B, Tan G, Arnold P, Fehlings. M, Kopjar B, Arnold P, Ibrahim A, Tetrault. L, Kopjar B, Arnold P, Fehlings. M, Sundararajan K, Eng. S, St-Pierre G, Nataraj A, Urquhart J, Rosas-Arellano P, Tallon C, Gurr K, Siddiqi F, Bailey S, Bailey C, Sundararajan K, Rampersaud. R, Rosa-Arellano P, Tallon C, Bailey S, Gurr K, Bailey. C, Parker R, Milili L, Goss B, Malham. G, Green A, McKeon M, Abraham. E, Lafave L, Parnell J, Rempel J, Moriartey S, Andreas Y, Wilson P, Hepler C, Ray H, Hu. R, Ploumis A, Hess K, Wood. K, Yarascavitch B, Madden K, Ghert M, Drew B, Bhandari M, Kwok D, Tu YS, Salter. M, Hadlow. A, Tso P, Walker K, Lewis S, Davey J, Mahomed N, Coyte. P, Mac-Thiong JM, Roy-Beaudry M, Turgeon I, Labelle H, deGuise J, Parent. S, Jack A, Fox R, Nataraj A, Paquette S, Leroux T, Yee A, Ahn H, Broad R, Fisher C, Hall H, Nataraj A, Hedden D, Christie S, Carey T, Mehta V, Fehlings M, Wadey. V, Dear T, Hashem. M, Fourney D, Goldstein S, Bodrogi A, Lipkus M, Dear T, Keshen S, Veillette C, Gandhi R, Adams D, Briggs N, Davey J, Fehlings M, Lau J, Lewis S, Magtoto R, Marshall K, Massicotte E, Ogilvie-Harris D, Sarro A, Syed K, Mohamed. N, Perera S, Taha A, Urquhart J, Gurr K, Siddiqi F, Bailey C, Thomas K, Cho R, Swamy G, Power C, Henari S, Lenehan. B, McIntosh G, Hall H, Hoffman. C, Karachi A, Pazionis T, AlShaya O, Green A, McKeon M, Manson. N, Green A, McKeon M, Manson. N, Green A, McKeon M, Murray J, Abraham. E, Thomas K, Suttor S, Goyal T, Littlewood J, Bains I, Bouchard J, Hu R, Jacobs B, Cho R, Swamy G, Johnson M, Pelleck V, Amad Y, Ramos E, Glazebrook C. Combined Spine Conference of the Canadian Spine Society New Zealand Orthopaedic Spine Society, Spine Society of Australia: Fairmont Château Lake Louise, Lake, Louise, Alberta, Tuesday, Feb. 25 to Saturday, Mar. 1, 20141.1.01 The use of suspension radiographs to predict LIV tilt.1.1.02 Surgical correction of adolescent idiopathic scoliosis without fusion: an animal model.1.1.03 Are full torso surface topography postural measurements more sensitive to change than back only parameters in adolescents with idiopathic scoliosis and a main thoracic curve?1.2.04 Restoration of thoracic kyphosis in adolescent idiopathic kyphosis: comparative radiographic analysis of round versus rail rods.1.2.05 Scoliosis surgery in spastic quadriplegic cerebral palsy: Is fusion to the pelvis always necessary? A 4–18-year follow-up study.1.2.06 Identification and validation of pain-related biomarkers surrounding spinal surgery in adolescents.1.3.07 Cervical sagittal deformity develops after PJK in adult throacolumbar deformity correction: radiographic analysis using a novel global sagittal angular parameter, the CTPA.1.3.08 Impact of obesity on complications and patient-reported outcomes in adult spinal deformity surgery.1.3.09 The T1 pelvic angle, a novel radiographic measure of sagittal deformity, accounts for both pelvic retroversion and truncal inclination and correlates strongly with HRQOL.1.4.10 Determining cervical sagittal deformity when it is concurrent with thoracolumbar deformity.1.4.11 The influence of sagittal balance and pelvic parameters on the outcome of surgically treated patients with degenerative spondylolisthesis.1.4.12 Predictors of degenerative spondylolisthesis and loading translation in surgical lumbar spinal stenosis patients.2.1.13 Mechanical allodynia following disc herniation requires intraneural macrophage infiltration and can be blocked by systemic selenium delivery or attenuation of BDNF activity.2.1.14 The effect of alanyl-glutamine on epidural fibrosis in a rat laminectomy model.2.1.15 Anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2: a prospective study of complications.2.2.16 2-year results of a Canadian, multicentre, blinded, pilot study of a novel peptide in promoting lumbar spine fusion.2.2.17 Comparative outcomes and cost-utility following surgical treatment of focal lumbar spinal stenosis compared with osteoarthritis of the hip or knee: long-term change in health-related quality of life.2.2.18 Changes in objectively measured walking performance, function, and pain following surgery for spondylolisthesis and lumbar spinal stenosis.2.3.19 A prospective multicentre observational data-monitored study of minimally invasive fusion to treat degenerative lumbar disorders: complications and outcomes at 1-year follow-up.2.3.20 Assessment and classification of subsidence in lateral interbody fusion using serial computed tomography.2.3.21 Predictors of willingness to undergo spinal and orthopaedic surgery after surgical consultation.2.4.22 Indirect foraminal decompression is independent of facet arthropathy in extreme lateral interbody fusion.2.4.23 Cervical artificial disc replacement with ProDisc-C: clinical and radiographic outcomes with long-term follow-up.2.4.24 Tantalum trabecular metal implants in anterior cervical corpectomy and fusion.3.1.25 Hemangiomas of the spine: results of surgical management and prognostic variables for local recurrence and mortality in a multicentre study.3.1.26 Chondrosarcomas of the spine: prognostic variables for local recurrence and mortality in a multicentre study.3.1.27 Risk factors for recurrence of surgically treated spine schwannomas: analysis of 169 patients from a multicentre international database.3.2.28 Survival pattern and the effect of surgery on health related quality of life and functional outcome in patients with metastatic epidural spinal cord compression from lung cancer — the AOSpine North America prospective multicentre study.3.2.29 A biomechanical assessment of kyphoplasty as a stand-alone treatment in a human cadaveric burst fracture model.3.2.30 What is safer in incompetent vertebrae with posterior wall defects, kyphoplasty or vertebroplasty: a study in vertebral analogs.3.3.31 Feasibility of recruiting subjects for acute spinal cord injury (SCI) clinical trials in Canada.3.3.32 Prospective analysis of adverse events in elderly patients with traumatic spinal cord injury.3.3.33 Does traction before surgery influence time to neural decompression in patients with spinal cord injury?3.4.34 Current treatment of individuals with traumatic spinal cord injury: Do we need age-specific guidelines?3.4.35 Current surgical practice for traumatic spinal cord injury in Canada.3.4.36 The importance of “time to surgery” for traumatic spinal cord injured patients: results from an ambispective Canadian cohort of 949 patients.3.5.37 Assessment of a novel coil-shaped radiofrequency probe in the porcine spine.3.5.38 The effect of norepinephrine and dopamine on cerebrospinal fluid pressure after acute spinal cord injury.3.5.39 The learning curve of pedicle screw placement: How many screws are enough?4.1.40 Preliminary report from the Ontario Inter-professional Spine Assessment and Education Clinics (ISAEC).4.1.41 A surrogate model of the spinal cord complex for simulating bony impingement.4.1.42 Clinical and surgical predictors of specific complications following surgery for the treatment of degenerative cervical myelopathy: results from the multicentre, prospective AOSpine international study on 479 patients.4.2.43 Outcomes of surgical management of cervical spondylotic myelopathy: results of the prospective, multicentre, AOSpine international study in 479 patients.4.2.44 A clinical prediction rule for clinical outcomes in patients undergoing surgery for degenerative cervical myelopathy: analysis of an international AOSpine prospective multicentre data set of 757 subjects.4.2.45 The prevalence and impact of low back and leg pain among aging Canadians: a cross-sectional survey.4.3.46 Adjacent segment pathology: Progressive disease course or a product of iatrogenic fusion?4.3.47 Natural history of degenerative lumbar spondylolisthesis in patients with spinal stenosis.4.3.48 Changes in self-reported clinical status and health care utilization during wait time for surgical spine consultation: a prospective observational study.4.3.49 The Canadian surgical wait list for lumbar degenerative spinal stenosis has a detrimental effect on patient outcomes.4.3.50 Segmental lordosis is independent of interbody cage position in XLIF.4.3.51 Elevated patient BMI does not negatively affect self-reported outcomes of thoracolumbar surgery.1.5.52 The Spinal Stenosis Pedometer and Nutrition Lifestyle Intervention (SSPANLI): development and pilot.1.5.53 Study evaluating the variability of surgical strategy planning for patients with adult spinal deformity.1.5.54 Atlantoaxial instability in acute odontoid fractures is associated with nonunion and mortality.1.5.55 Peripheral hypersensitivity to subthreshold stimuli persists after resolution of acute experimental disc-herniation neuropathy.1.5.56 Radiation induced lumbar spinal osteonecrosis: case report and literature review.1.5.57 Comparative outcomes and cost-utility following surgical treatment of focal lumbar spinal stenosis compared with osteoarthritis of the hip or knee: Part 2 — estimated lifetime incremental cost-utility ratios.1.5.58 A predictive model of progression for adolescent idiopathic scoliosis based on 3D spine parameters at first visit.1.5.59 Development of a clinical prediction model for surgical decision making in patients with degenerative lumbar spine disease.2.5.60 Canadian spine surgery fellowship education: evaluating opportunity in developing a nationally based training curriculum.2.5.61 Pedicle subtraction osteotomy for severe proximal thoracic junctional kyphosis.2.5.62 A comparison of spine surgery referrals triaged through a multidisciplinary care pathway versus conventional referrals.2.5.63 Results and complications of posterior-based 3 column osteotomies in patients with previously fused spinal deformities.2.5.64 Orthopaedic Surgical AdVerse Event Severity (Ortho-SAVES) system: identifying opportunities for improved patient safety and resource utilization.2.5.65 Spontaneous spinal extra-axial haematomas — surgical experience in Otago and Southland 2011–2013.2.5.66 Obesity and spinal epidural lipomatosis in cauda equina syndrome.2.5.67 Factors affecting restoration of lumbar lordosis in adult degenerative scoliosis patients treated with lateral trans-psoas interbody fusion.3.6.68 Systematic review of complications in spinal surgery: a comparison of retrospective and prospective study design.3.6.69 Postsurgical rehabilitation patients have similar fear avoidance behaviour levels as those in nonoperative care.3.6.70 Outcomes of surgical treatment of adolescent spondyloptosis: a case series.3.6.71 Surgical success in primary versus revision thoracolumbar spine surgery.3.6.72 The effect of smoking on subjective patient outcomes in thoracolumbar surgery.3.6.73 Modelling patient recovery to predict outcomes following elective thoracolumbar surgery for degenerative pathologies.3.6.74 Outcomes from trans-psoas versus open approaches in the treatment of adult degenerative scoliosis.3.6.75 Lumbar spinal stenosis and presurgical assessment: the impact of walking induced strain on a performance-based outcome measure. Can J Surg 2014. [DOI: 10.1503/cjs.005614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
49
|
Jack A. US drug firm Pfizer seeks to buy UK company AstraZeneca. BMJ 2014; 348:g2986. [PMID: 24778296 DOI: 10.1136/bmj.g2986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
50
|
|